

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number  
**WO 2005/011735 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 39/395**,  
48/00, C12N 5/00, 5/06, 5/16, 15/00

(74) Agents: CALDWELL, John, W. et al.; Woodcock Washburn LLP, 46th Floor, One Liberty Place, Philadelphia, PA 19103 (US).

(21) International Application Number:  
PCT/US2004/024436

(22) International Filing Date: 29 July 2004 (29.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/491,310 29 July 2003 (29.07.2003) US

(71) Applicant (for all designated States except US): **MORPHOTEK, INC.** [US/US]; 210 Welsh Pool Road, Exton, PA 19341 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **GRASSO, Luigi** [IT/US]; 707 Conshohocken State Road, Bala Cynwyd, PA 19004 (US). **NICOLAIDES, Nicholas, E.** [US/US]; 4 Cider Mill Court, Boothwyn, PA 19061 (US). **SANDS, Howard** [US/US]; 2417 Landon Drive, Wilmington, DE (US). **SASS, Philop, M.** [US/US]; \* (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: ANTIBODIES AND METHODS FOR GENERATING GENETICALLY ALTERED ANTIBODIES WITH ENHANCED EFFECTOR FUNCTION



(57) Abstract: Dominant negative alleles of human mismatch repair genes can be used to generate hypermutable cells and organisms. By introducing these genes into cells and transgenic animals new cell lines and animal varieties with novel and useful properties can be prepared more efficiently than by relying on the natural rate of mutation. These methods are useful for generating genetic diversity within immunoglobulin genes directed against an antigen of interest to produce altered antibodies with enhanced biochemical activity. Moreover, these methods are useful for generating antibody-producing cells with increased level of antibody production. The invention also provides methods for increasing the effector function of monoclonal antibodies and monoclonal antibodies with increased effector function.



**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## **ANTIBODIES AND METHODS FOR GENERATING GENETICALLY ALTERED ANTIBODIES WITH ENHANCED EFFECTOR FUNCTION**

### **CROSS REFERENCE TO RELATED APPLICATIONS**

[0001] This claims the benefit of U.S. Provisional Application 60/491,310, filed July 29, 2003, the entire contents of which are hereby incorporated by reference.

### **FIELD OF THE INVENTION**

[0002] The invention is related to the area of antibody effector function and cellular production. In particular, it is related to the field of mutagenesis.

### **BACKGROUND OF THE INVENTION**

[0003] The use of antibodies to block the activity of foreign and/or endogenous polypeptides provides an effective and selective strategy for treating the underlying cause of disease. For example, monoclonal antibodies (MAb), such as the FDA-approved ReoPro (Glaser, V. (1996) "Can ReoPro repolish tarnished monoclonal therapeutics?" *Nat. Biotechnol.* 14:1216-1217), an anti-platelet MAb from Centocor; Herceptin (Weiner, L.M. (1999) "Monoclonal antibody therapy of cancer" *Semin. Oncol.* 26:43-51), an anti-Her2/neu MAb from Genentech; and Synagis (Saez-Llorens, X.E., et al. (1998) "Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia" *Pediat. Infect. Dis. J.* 17:787-791), an anti-respiratory syncytial virus MAb produced by Medimmune, have been used as effective therapeutics.

[0004] Standard methods for generating MAbs against candidate protein targets are known by those skilled in the art. Briefly, rodents such as mice or rats are injected with a purified

antigen in the presence of adjuvant to generate an immune response (Shield, C.F., *et al.* (1996) A cost-effective analysis of OKT3 induction therapy in cadaveric kidney transplantation. *Am. J. Kidney Dis.* 27:855-864). Rodents with positive immune sera are sacrificed and splenocytes are isolated. Isolated splenocytes are fused to melanomas to produce immortalized cell lines that are then screened for antibody production. Positive lines are isolated and characterized for antibody production. The direct use of rodent MAbs as human therapeutic agents were confounded by the fact that human anti-rodent antibody (HARA) responses occurred in a significant number of patients treated with the rodent-derived antibody (Khazaeli, M.B., *et al.*, (1994) Human immune response to monoclonal antibodies. *J. Immunother.* 15:42-52). In order to circumvent the problem of HARA, the grafting of the complementarity determining regions (CDRs), which are the critical motifs found within the heavy and light chain variable regions of the immunoglobulin (Ig) subunits making up the antigen binding domain, onto a human antibody backbone found these chimeric molecules are able to retain their binding activity to antigen while lacking the HARA response (Emery, S.C., and Harris, W.J. "Strategies for humanizing antibodies" In: ANTIBODY ENGINEERING C.A.K. Borrebaeck (Ed.) Oxford University Press, N.Y. 1995. pp. 159-183). A common problem that exists during the "humanization" of rodent-derived MAbs (referred to hereon as HAb) is the loss of binding affinity due to conformational changes in the 3-dimensional structure of the CDR domain upon grafting onto the human Ig backbone (U.S. Patent No. 5,530,101 to Queen *et al.*). To overcome this problem, additional HAb vectors usually need to be engineered by inserting or deleting additional amino acid residues within the framework region and/or within the CDR coding region itself in order to recreate high affinity HAb (U.S. Patent No. 5,530,101 to Queen *et al.*). This process is a very time consuming procedure that involves the use of expensive computer modeling programs to predict changes that may lead to a high affinity HAb. In some instances, the affinity of the HAb is never restored to that of the MAb, rendering them of little therapeutic use.

[0005] Another problem that exists in antibody engineering is the generation of stable, high yielding producer cell lines that are required for manufacturing of the molecule for clinical materials. Several strategies have been adopted in standard practice by those skilled in the art to circumvent this problem. One method is the use of Chinese Hamster Ovary (CHO) cells transfected with exogenous Ig fusion genes containing the grafted human light and heavy chains to produce whole antibodies or single chain antibodies, which are a chimeric molecule containing both light and heavy chains that form an antigen-binding polypeptide (Reff, M.E. (1993) High-level production of recombinant immunoglobulins in mammalian cells. *Curr. Opin. Biotechnol.* 4:573-576). Another method employs the use of human lymphocytes derived from

transgenic mice containing a human grafted immune system or transgenic mice containing a human Ig gene repertoire. Yet another method employs the use of monkeys to produce primate MAbs, which have been reported to lack a human anti-monkey response (Neuberger, M., and Gruggermann, M. (1997) Monoclonal antibodies. Mice perform a human repertoire. *Nature* 386:25-26). In all cases, the generation of a cell line that is capable of generating sufficient amounts of high affinity antibody poses a major limitation for producing sufficient materials for clinical studies. Because of these limitations, the utility of other recombinant systems such as plants are currently being explored as systems that will lead to the stable, high-level production of humanized antibodies (Fiedler, U., and Conrad, U. (1995) High-level production and long-term storage of engineered antibodies in transgenic tobacco seeds. *Bio/Technology* 13:1090-1093).

**[0006]** Still another aspect of antibody function is the effector mechanisms of the Mab. One of many possible ways to increase effector function of antibodies is via changes in glycosylation. This topic has been recently reviewed by Raju who summarized the proposed importance of the oligosaccharides found on human IgGs with their degree of effector function (Raju, TS. *BioProcess International* April 2003. 44-53). According to Wright and Morrison, the microheterogeneity of human IgG oligosaccharides can affect biological functions such as complement dependent cytotoxicity (CDC) and antibody-dependent cytotoxicity (ADCC), binding to various Fc receptors, and binding to C1q protein (Wright A. Morrison SL. TIBTECH 1997, 15 26-32). It is well documented that glycosylation patterns of antibodies can differ depending on the producing cell and the cell culture conditions (Raju, TS. *BioProcess International* April 2003. 44-53). Such differences can lead to changes in both effector function and pharmacokinetics (Israel EJ, Wilsker DF, Hayes KC, Schoenfeld D, Simister NE. *Immunology*. 1996 Dec;89(4):573-578; Newkirk MM, Novick J, Stevenson MM, Fournier Mi, Apostolakis P. *Clin. Exp.* 1996 Nov;106(2):259-64). Differences in effector function may be related to the IgGs ability to bind to the Fcγ receptors (FcγRs) on the effector cells. Shields, *et al.*, have shown that IgG<sub>1</sub> with variants in amino acid sequence that have improved binding to FcγR can exhibit up to 100% enhanced ADCC using human effector cells (Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA, Presta LG. *J Biol Chem*. 2001 Mar 2;276(9):6591-604). While these variants include changes in amino acids not found at the binding interface, both the nature of the sugar component as well as its structural pattern may also contribute to the differences seen. In addition, the presence or absence of fucose in the oligosaccharide component of an IgG<sub>1</sub> can improve binding and ADCC (Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. *J Biol Chem*. 2002 Jul

26;277(30):26733-40). An IgG<sub>1</sub> that lacked a fucosylated carbohydrate linked to Asn<sup>297</sup> exhibited normal receptor binding to the Fcγ receptor. In contrast, binding to the FcγRIIA receptor was improved 50% and accompanied by enhanced ADCC, especially at lower antibody concentrations.

[0007] Work by Shinkawa, *et al.*, demonstrated that an antibody to the human IL-5 receptor produced in a rat hybridoma showed more than 50% higher ADCC when compared to the antibody produced in Chinese hamster ovary cells (CHO)(Shinkawa T, Nakamura K, Yaman N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K. *J Biol Chem*. 2003 Jan 31;278(5):3466-73). Monosaccharide composition and oligosaccharide profiling showed that the rat hybridoma-produced IgG<sub>1</sub> had a lower content of fucose than the CHO-produced protein. The authors concluded that the lack of fucosylation of an IgG<sub>1</sub> has a critical role in enhancement of ADCC activity.

[0008] A different approach was taken by Umana, *et al.*, who changed the glycosylation pattern of chCE7, a chimeric IgG<sub>1</sub> anti-neuroblastoma antibody (Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. *Nat Biotechnol*. 1999 Feb; 17(2): 176-80). Using tetracycline, they regulated the activity of a glycosyltransferase enzyme (GnTIII) which bisects oligosaccharides that have been implicated in ADCC activity. The ADCC activity of the parent antibody was barely above background level. Measurement of ADCC activity of the chCE7 produced at different tetracycline levels showed an optimal range of GnTIII expression for maximal chCE7 *in vitro* ADCC activity. This activity correlated with the level of constant region-associated, bisected complex oligosaccharide. Newly optimized variants exhibited substantial ADCC activity.

[0009] A method for generating diverse antibody sequences within the variable domain that results in HAbs and MAbs with high binding affinities to antigens would be useful for the creation of more potent therapeutic and diagnostic reagents respectively. Moreover, the generation of randomly altered nucleotide and polypeptide residues throughout an entire antibody molecule will result in new reagents that are less antigenic and/or have beneficial pharmacokinetic properties. The invention described herein is directed to the use of random genetic mutation throughout an antibody structure *in vivo* by blocking the endogenous mismatch repair (MMR) activity of a host cell producing immunoglobulins that encode biochemically active antibodies. The invention also relates to methods for repeated *in vivo* genetic alterations and selection for antibodies with enhanced binding and pharmacokinetic profiles. The methods of the invention may be used to enhance the effector function of the antibodies.

[0010] In addition, the ability to develop genetically altered host cells that are capable of secreting increased amounts of antibody will also provide a valuable method for creating cell hosts for product development. The invention described herein is directed to the creation of genetically altered cell hosts with increased antibody production via the blockade of MMR.

[0011] The invention facilitates the generation of antibodies with enhanced effector function and the production of cell lines with elevated levels of antibody production. Other advantages of the present invention are described in the examples and figures described herein.

## SUMMARY OF THE INVENTION

[0012] The invention provides methods for generating genetically altered antibodies (including single chain molecules) and antibody producing cell hosts *in vitro* and *in vivo*, whereby the antibody possesses a desired biochemical property(s), such as, but not limited to, increased antigen binding, increased gene expression, enhanced effector function and/or enhanced extracellular secretion by the cell host. One method for identifying antibodies with increased binding activity or cells with increased antibody production is through the screening of MMR defective antibody producing cell clones that produce molecules with enhanced binding properties, enhanced effector function such as (but not limited to) antibody-dependent cellular cytotoxicity (ADCC), or clones that have been genetically altered to produce enhanced amounts of antibody product.

[0013] The antibody producing cells suitable for use in the invention include, but are not limited to rodent, primate, or human hybridomas or lymphoblastoids; mammalian cells transfected with and expressing exogenous Ig subunits or chimeric single chain molecules; plant cells, yeast or bacteria transfected with and expressing exogenous Ig subunits or chimeric single chain molecules.

[0014] Thus, the invention provides methods for making hypermutable antibody-producing cells by introducing a polynucleotide comprising a dominant negative allele of a mismatch repair gene into cells that are capable of producing antibodies. The cells that are capable of producing antibodies include cells that naturally produce antibodies, and cells that are engineered to produce antibodies through the introduction of immunoglobulin encoding sequences. Conveniently, the introduction of polynucleotide sequences into cells is accomplished by transfection.

[0015] The invention also provides methods of making hypermutable antibody producing cells by introducing a dominant negative mismatch repair (MMR) gene such as *PMS2* (preferably human *PMS2*), *MLH1*, *PMS1*, *MSH1*, or *MSH2* into cells that are capable of producing antibodies. The dominant negative allele of a mismatch repair gene may be a

truncation mutation of a mismatch repair gene (preferably a truncation mutation at codon 134, or a thymidine at nucleotide 424 of wild-type *PMS2*). The invention also provides methods in which mismatch repair gene activity is suppressed. This may be accomplished, for example, using antisense molecules directed against the mismatch repair gene or transcripts.

[0016] Other embodiments of the invention provide methods for making a hypermutable antibody producing cells by introducing a polynucleotide comprising a dominant negative allele of a mismatch repair gene into fertilized eggs of animals. These methods may also include subsequently implanting the eggs into pseudo-pregnant females whereby the fertilized eggs develop into a mature transgenic animal. The mismatch repair genes may include, for example, *PMS2* (preferably human *PMS2*), *MLH1*, *PMS1*, *MSH1*, or *MSH2*. The dominant negative allele of a mismatch repair gene may be a truncation mutation of a mismatch repair gene (preferably a truncation mutation at codon 134, or a thymidine at nucleotide 424 of wild-type *PMS2*).

[0017] The invention further provides homogeneous compositions of cultured, hypermutable, mammalian cells that are capable of producing antibodies and contain a dominant negative allele of a mismatch repair gene. The mismatch repair genes may include, for example, *PMS2* (preferably human *PMS2*), *MLH1*, *PMS1*, *MSH1*, or *MSH2*. The dominant negative allele of a mismatch repair gene may be a truncation mutation of a mismatch repair gene (preferably a truncation mutation at codon 134, or a thymidine at nucleotide 424 of wild-type *PMS2*). The cells of the culture may contain *PMS2*, (preferably human *PMS2*), *MLH1*, or *PMS1*; or express a human *mutL* homolog, or the first 133 amino acids of hPMS2.

[0018] The invention further provides methods for generating a mutation in an immunoglobulin gene of interest by culturing an immunoglobulin producing cell selected for an immunoglobulin of interest wherein the cell contains a dominant negative allele of a mismatch repair gene. The properties of the immunoglobulin produced from the cells can be assayed to ascertain whether the immunoglobulin gene harbors a mutation. The assay may be directed to analyzing a polynucleotide encoding the immunoglobulin, or may be directed to the immunoglobulin polypeptide itself.

[0019] The invention also provides methods for generating a mutation in a gene affecting antibody production in an antibody-producing cell by culturing the cell expressing a dominant negative allele of a mismatch repair gene, and testing the cell to determine whether the cell harbors mutations within the gene of interest, such that a new biochemical feature (*e.g.*, over-expression and/or secretion of immunoglobulin products) is generated. The testing may include analysis of the steady state expression of the immunoglobulin gene of interest, and/or



analysis of the amount of secreted protein encoded by the immunoglobulin gene of interest. The invention also embraces prokaryotic and eukaryotic transgenic cells made by this process, including cells from rodents, non-human primates and humans.

[0020] Other aspects of the invention encompass methods of reversibly altering the hypermutability of an antibody producing cell, in which an inducible vector containing a dominant negative allele of a mismatch repair gene operably linked to an inducible promoter is introduced into an antibody-producing cell. The cell is treated with an inducing agent to express the dominant negative mismatch repair gene (which can be *PMS2* (preferably human *PMS2*), *MLH1*, or *PMS1*). Alternatively, the cell may be induced to express a human *mutL* homolog or the first 133 amino acids of hPMS2. In another embodiment, the cells may be rendered capable of producing antibodies by co-transfecting a preselected immunoglobulin gene of interest. The immunoglobulin genes of the hypermutable cells, or the proteins produced by these methods may be analyzed for desired properties, and induction may be stopped such that the genetic stability of the host cell is restored.

[0021] The invention also embraces methods of producing genetically altered antibodies by transfecting a polynucleotide encoding an immunoglobulin protein into a cell containing a dominant negative mismatch repair gene (either naturally or in which the dominant negative mismatch repair gene was introduced into the cell), culturing the cell to allow the immunoglobulin gene to become mutated and produce a mutant immunoglobulin, screening for a desirable property of said mutant immunoglobulin protein, isolating the polynucleotide molecule encoding the selected mutant immunoglobulin possessing the desired property, and transfecting said mutant polynucleotide into a genetically stable cell, such that the mutant antibody is consistently produced without further genetic alteration. The dominant negative mismatch repair gene may be *PMS2* (preferably human *PMS2*), *MLH1*, or *PMS1*. Alternatively, the cell may express a human *mutL* homolog or the first 133 amino acids of hPMS2.

[0022] The invention further provides methods for generating genetically altered cell lines that express enhanced amounts of an antigen binding polypeptide. These antigen-binding polypeptides may be, for example, immunoglobulins. The methods of the invention also include methods for generating genetically altered cell lines that secrete enhanced amounts of an antigen binding polypeptide. The cell lines are rendered hypermutable by dominant negative mismatch repair genes that provide an enhanced rate of genetic hypermutation in a cell producing antigen-binding polypeptides such as antibodies. Such cells include, but are not limited to hybridomas. Expression of enhanced amounts of antigen binding polypeptides may be through enhanced

transcription or translation of the polynucleotides encoding the antigen binding polypeptides, or through the enhanced secretion of the antigen binding polypeptides, for example.

[0023] Methods are also provided for creating genetically altered antibodies *in vivo* by blocking the MMR activity of the cell host, or by transfecting genes encoding for immunoglobulin in a MMR defective cell host.

[0024] Antibodies with increased binding properties to an antigen due to genetic changes within the variable domain are provided in methods of the invention that block endogenous MMR of the cell host. Antibodies with increased binding properties to an antigen due to genetic changes within the CDR regions within the light and/or heavy chains are also provided in methods of the invention that block endogenous MMR of the cell host.

[0025] The invention provides methods of creating genetically altered antibodies in MMR defective Ab producer cell lines with enhanced pharmacokinetic properties in host organisms including but not limited to rodents, primates, and man.

[0026] These and other aspects of the invention are provided by one or more of the embodiments described below. In one embodiment of the invention, a method for making an antibody producing cell line hypermutable is provided. A polynucleotide encoding a dominant negative allele of a MMR gene is introduced into an antibody-producing cell. The cell becomes hypermutable as a result of the introduction of the gene.

[0027] In another embodiment of the invention, a method is provided for introducing a mutation into an endogenous gene encoding for an immunoglobulin polypeptide or a single chain antibody. A polynucleotide encoding a dominant negative allele of a MMR gene is introduced into a cell. The cell becomes hypermutable as a result of the introduction and expression of the MMR gene allele. The cell further comprises an immunoglobulin gene of interest. The cell is grown and tested to determine whether the gene encoding for an immunoglobulin or a single chain antibody of interest harbors a mutation. In another aspect of the invention, the gene encoding the mutated immunoglobulin polypeptide or single chain antibody may be isolated and expressed in a genetically stable cell. In a preferred embodiment, the mutated antibody is screened for at least one desirable property such as, but not limited to, enhanced binding characteristics.

[0028] In another embodiment of the invention, a gene or set of genes encoding for Ig light and heavy chains or a combination therein are introduced into a mammalian cell host that is MMR defective. The cell is grown, and clones are analyzed for antibodies with enhanced binding characteristics.

**[0029]** In another embodiment of the invention, a method is provided for producing new phenotypes of a cell. A polynucleotide encoding a dominant negative allele of a MMR gene is introduced into a cell. The cell becomes hypermutable as a result of the introduction of the gene. The cell is grown. The cell is tested for the expression of new phenotypes where the phenotype is enhanced secretion of a polypeptide.

**[0030]** The invention also provides antibodies having increased affinity for antigen comprising immunoglobulin molecules wherein a substitution has been made for at least one amino acid in the variable domain of the heavy and/or light chain. In some embodiments, the substitution is in a position wherein the parental amino acid in that position is an amino acid with a non-polar side chain. In some embodiments the parental amino acid is substituted with a different amino acid that has a non-polar side chain. In other embodiments, the parental amino acid is replaced with a proline or hydroxyproline. In some embodiments, the substitution(s) are made in the framework regions of the heavy and/or light chain variable domains. In some embodiments, the substitution(s) are made within the first framework region of the heavy chain. In some embodiments, the substitution(s) are made within the second framework region of the light chain. In some embodiments, the substitutions are made within the first framework region of the heavy chain and the second framework region of the light chain. In some embodiments, a substitution is made at position 6 of the first framework region of the heavy chain as shown in SEQ ID NO: 18. In some embodiments a substitution is made at position 22 of the second framework region of the light chain as shown in SEQ ID NO:21. For the specific position mutations, in some embodiments the amino acid substitution is a proline or hydroxyproline.

**[0031]** The invention also provides methods for increasing the affinity of an antibody for an antigen comprising substituting an amino acid within the variable domain of the heavy or light chain of the subject antibody with another amino acid having a non-polar side chain. In some embodiments, a proline is substituted for the original amino acid at the position. In some embodiments, proline is used to substitute for another amino acid having a non-polar side chain. In some embodiments alanine and/or leucine is replaced by proline. In certain embodiments, the amino acid in position 6 of the first framework region of the heavy chain of the antibody as shown in SEQ ID NO: 18 is replaced with a proline. In other embodiments, the amino acid in position 22 of the second framework region of the light chain variable domain as shown in SEQ ID NO:21 is replaced with proline. The invention also provides antibodies produced by these methods.

**[0032]** The antibodies produced in the invention may be made using the process of the invention wherein a dominant negative allele of a mismatch repair gene is introduced into the

antibody producing cell and the cell becomes hypermutable as described more fully herein. Alternatively, one may disrupt mismatch repair using chemical inhibitors of mismatch repair, such as using anthracene and/or its derivatives as described in PCT Publication No. WO 02/054856, published July 18, 2002, which is specifically incorporated herein in its entirety. The cells treated with the chemicals that disrupt mismatch repair or which express a dominant negative mismatch repair gene become hypermutable. The antibodies produced by the hypermutable cells are screened for increased affinity, and those antibodies comprising the amino acid substitutions described above display increased affinity for antigen. The cells producing the antibodies which have the increased affinity and the molecular characteristics described herein may be rendered genetically stable again by withdrawing the chemical inhibitor, or by rendering the cells genetically stable through the inactivation of the expression of the dominant negative allele. For example, a dominant negative allele that is under the control of an inducible promoter may be inactivated by withdrawing the inducer. Alternatively, the dominant negative allele may be knocked out, or a CRE-LOX expression system may be used whereby the dominant negative allele is spliced from the genome once the cells containing a genetically diverse immunoglobulin has been established.

[0033] In other embodiments, one of skill in the art may use any known method of introducing mutations into proteins and selecting for antibodies having higher affinity with the amino acid substitutions described above. Methods of introducing mutations may be random, such as chemical mutagenesis, or may be specific, such as site-directed mutagenesis. Methods for random and specific mutagenesis are well-known in the art and include, but are not limited to, for example, chemical mutagenesis (e.g., using such chemicals as methane sulfonate, dimethyl sulfonate, O6-methyl benzadine, methylnitrosourea (MNU), and ethylnitrosourea (ENU)); oligonucleotide-mediated site-directed mutagenesis; alanine scanning; and PCR mutagenesis (see, for example, Kunkel *et al.* (1991) *Methods Enzymol.* 204:125-139), site-directed mutagenesis; Cramer *et al.* (1995) *BioTechniques* 18(2):194-196, cassette mutagenesis; and Haught *et al.* (1994) *BioTechniques* 16(1):47-48, restriction selection mutagenesis).

[0034] These and other embodiments of the invention provide the art with methods that can generate enhanced mutability in cells and animals as well as providing cells and animals harboring potentially useful mutations for the large-scale production of high affinity antibodies with beneficial pharmacokinetic profiles.

## BRIEF DESCRIPTION OF THE DRAWINGS

[0035] **Figure 1.** Hybridoma cells stably expressing PMS2 and PMS134 MMR genes. Shown is steady state mRNA expression of MMR genes transfected into a murine hybridoma

cell line. Stable expression was found after 3 months of continuous growth. The (-) lanes represent negative controls where no reverse transcriptase was added, and the (+) lanes represent samples reverse transcribed and PCR amplified for the MMR genes and an internal housekeeping gene as a control.

**[0036] Figure 2.** Creation of genetically hypermutable hybridoma cells. Dominant negative MMR gene alleles were expressed in cells expressing a MMR-sensitive reporter gene. Dominant negative alleles such as PMS134 and the expression of MMR genes from other species results in antibody producer cells with a hypermutable phenotype that can be used to produce genetically altered immunoglobulin genes with enhanced biochemical features as well as lines with increased Ig expression and/or secretion. Values shown represent the amount of converted CPRG substrate which is reflective of the amount of function of  $\beta$ -galactosidase contained within the cell from genetic alterations within the pCAR-OF reporter gene. Higher amounts of  $\beta$ -galactosidase activity reflect a higher mutation rate due to defective MMR.

**[0037] Figure 3.** Screening method for identifying antibody-producing cells containing antibodies with increased binding activity and/or increased expression/secretion

**[0038] Figure 4.** Generation of a genetically altered antibody with an increased binding activity. Shown are ELISA values from 96-well plates, screened for antibodies specific to hIgE. Two clones with a high binding value were found in HB134 cultures.

**[0039] Figure 5.** Sequence alteration within variable chain of an antibody (a mutation within the light chain variable region in MMR-defective HB134 antibody producer cells). Arrows indicate the nucleotide at which a mutation occurred in a subset of cells from a clone derived from HB 134 cells. **Panel A:** The change results in a Thr to Ser change within the light chain variable region. The coding sequence is in the antisense direction. **Panel B:** The change results in a Pro to Leu change within the light chain variable region.

**[0040] Figure 6.** Generation of MMR-defective clones with enhanced steady state Ig protein levels. A Western blot of heavy chain immunoglobulins from HB134 clones with high levels of MAb (>500ngs/ml) within the conditioned medium shows that a subset of clones express higher steady state levels of immunoglobulins (Ig). The H36 cell line was used as a control to measure steady state levels in the parental strain. Lane 1: fibroblast cells (negative control); Lane 2: H36 cell; Lane 3: HB134 clone with elevated MAb levels; Lane 4: HB134 clone with elevated MAb levels; Lane 5: HB 134 clone with elevated MAb levels.

**[0041] Figure 7.** MORAb-003 is able to induce cytotoxicity in human ovarian tumor cells mediated by normal human PBMCs.

**DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS**

[0042] Methods have been discovered for developing hypermutable antibody-producing cells by taking advantage of the conserved mismatch repair (MMR) process of host cells. Dominant negative alleles of such genes, when introduced into cells or transgenic animals, increase the rate of spontaneous mutations by reducing the effectiveness of DNA repair and thereby render the cells or animals hypermutable. Hypermutable cells or animals can then be utilized to develop new mutations in a gene of interest. Blocking MMR in antibody-producing cells such as but not limited to: hybridomas; mammalian cells transfected with genes encoding for Ig light and heavy chains; mammalian cells transfected with genes encoding for single chain antibodies; eukaryotic cells transfected with Ig genes, can enhance the rate of mutation within these cells leading to clones that have enhanced antibody production and/or cells containing genetically altered antibodies with enhanced biochemical properties such as increased antigen binding. The process of MMR, also called mismatch proofreading, is carried out by protein complexes in cells ranging from bacteria to mammalian cells. A MMR gene is a gene that encodes for one of the proteins of such a mismatch repair complex. Although not wanting to be bound by any particular theory of mechanism of action, a MMR complex is believed to detect distortions of the DNA helix resulting from non-complementary pairing of nucleotide bases. The non-complementary base on the newer DNA strand is excised, and the excised base is replaced with the appropriate base, which is complementary to the older DNA strand. In this way, cells eliminate many mutations that occur as a result of mistakes in DNA replication.

[0043] Dominant negative alleles cause a MMR defective phenotype even in the presence of a wild-type allele in the same cell. An example of a dominant negative allele of a MMR gene is the human gene *hPMS2 -134*, which carries a truncating mutation at codon 134 (SEQ ID NO:15). The mutation causes the product of this gene to abnormally terminate at the position of the 134th amino acid, resulting in a shortened polypeptide containing the N-terminal 133 amino acids. Such a mutation causes an increase in the rate of mutations, which accumulate in cells after DNA replication. Expression of a dominant negative allele of a mismatch repair gene results in impairment of mismatch repair activity, even in the presence of the wild-type allele. Any allele which produces such effect can be used in this invention. Dominant negative alleles of a MMR gene can be obtained from the cells of humans, animals, yeast, bacteria, or other organisms. Such alleles can be identified by screening cells for defective MMR activity. Cells from animals or humans with cancer can be screened for defective mismatch repair. Cells from colon cancer patients may be particularly useful. Genomic DNA, cDNA, or mRNA from any cell encoding a MMR protein can be analyzed for variations from the wild type sequence.

Dominant negative alleles of a MMR gene can also be created artificially, for example, by producing variants of the *hPMS2-134* allele or other MMR genes. Various techniques of site-directed mutagenesis can be used. The suitability of such alleles, whether natural or artificial, for use in generating hypermutable cells or animals can be evaluated by testing the mismatch repair activity caused by the allele in the presence of one or more wild-type alleles, to determine if it is a dominant negative allele.

[0044] A cell or an animal into which a dominant negative allele of a mismatch repair gene has been introduced will become hypermutable. This means that the spontaneous mutation rate of such cells or animals is elevated compared to cells or animals without such alleles. The degree of elevation of the spontaneous mutation rate can be at least 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, 200-fold, 500-fold, or 1000-fold that of the normal cell or animal. The use of chemical mutagens such as but limited to methane sulfonate, dimethyl sulfonate, 06-methyl benzadine, MNU, ENU, etc. can be used in MMR defective cells to increase the rates an additional 10 to 100 fold that of the MMR deficiency itself.

[0045] According to one aspect of the invention, a polynucleotide encoding for a dominant negative form of a MMR protein is introduced into a cell. The gene can be any dominant negative allele encoding a protein, which is part of a MMR complex, for example, *PMS2*, *PMS1*, *MLH1*, or *MSH2*. The dominant negative allele can be naturally occurring or made in the laboratory. The polynucleotide can be in the form of genomic DNA, cDNA, RNA, or a chemically synthesized polynucleotide.

[0046] The polynucleotide can be cloned into an expression vector containing a constitutively active promoter segment (such as but not limited to CMV, SV40, Elongation Factor or LTR sequences) or to inducible promoter sequences such as the steroid inducible pIND vector (Invitrogen), where the expression of the dominant negative MMR gene can be regulated. The polynucleotide can be introduced into the cell by transfection.

[0047] According to another aspect of the invention, an immunoglobulin (Ig) gene, a set of Ig genes or a chimeric gene containing whole or parts of an Ig gene can be transfected into MMR- deficient cell hosts, the cell is grown and screened for clones containing genetically altered Ig genes with new biochemical features. MMR defective cells may be of human, primates, mammals, rodent, plant, yeast or of the prokaryotic kingdom. The mutated gene encoding the Ig with new biochemical features may be isolated from the respective clones and introduced into genetically stable cells (*i.e.*, cells with normal MMR) to provide clones that consistently produce Ig with the new biochemical features. The method of isolating the Ig gene encoding Ig with new biochemical features may be any method known in the art. Introduction of

the isolated polynucleotide encoding the Ig with new biochemical features may also be performed using any method known in the art, including, but not limited to transfection of an expression vector containing the polynucleotide encoding the Ig with new biochemical features. As an alternative to transfecting an Ig gene, a set of Ig genes or a chimeric gene containing whole or parts of an Ig gene into an MMR deficient host cell, such Ig genes may be transfected simultaneously with a gene encoding a dominant negative mismatch repair gene into a genetically stable cell to render the cell hypermutable.

[0048] Transfection is any process whereby a polynucleotide is introduced into a cell. The process of transfection can be carried out in a living animal, *e.g.*, using a vector for gene therapy, or it can be carried out *in vitro*, *e.g.*, using a suspension of one or more isolated cells in culture. The cell can be any type of eukaryotic cell, including, for example, cells isolated from humans or other primates, mammals or other vertebrates, invertebrates, and single celled organisms such as protozoa, yeast, or bacteria.

[0049] In general, transfection will be carried out using a suspension of cells, or a single cell, but other methods can also be applied as long as a sufficient fraction of the treated cells or tissue incorporates the polynucleotide so as to allow transfected cells to be grown and utilized. The protein product of the polynucleotide may be transiently or stably expressed in the cell. Techniques for transfection are well known. Available techniques for introducing polynucleotides include but are not limited to electroporation, transduction, cell fusion, the use of calcium chloride, and packaging of the polynucleotide together with lipid for fusion with the cells of interest. Once a cell has been transfected with the MMR gene, the cell can be grown and reproduced in culture. If the transfection is stable, such that the gene is expressed at a consistent level for many cell generations, then a cell line results.

[0050] An isolated cell is a cell obtained from a tissue of humans or animals by mechanically separating out individual cells and transferring them to a suitable cell culture medium, either with or without pretreatment of the tissue with enzymes, *e.g.*, collagenase or trypsin. Such isolated cells are typically cultured in the absence of other types of cells. Cells selected for the introduction of a dominant negative allele of a mismatch repair gene may be derived from a eukaryotic organism in the form of a primary cell culture or an immortalized cell line, or may be derived from suspensions of single-celled organisms.

[0051] A polynucleotide encoding for a dominant negative form of a MMR protein can be introduced into the genome of an animal by producing a transgenic animal. The animal can be any species for which suitable techniques are available to produce transgenic animals. For example, transgenic animals can be prepared from domestic livestock, *e.g.*, bovine, swine, sheep,



goats, horses, *etc.*; from animals used for the production of recombinant proteins, *e.g.*, bovine, swine, or goats that express a recombinant polypeptide in their milk; or experimental animals for research or product testing, *e.g.*, mice, rats, guinea pigs, hamsters, rabbits, *etc.* Cell lines that are determined to be MMR defective can then be used as a source for producing genetically altered immunoglobulin genes *in vitro* by introducing whole, intact immunoglobulin genes and/or chimeric genes encoding for single chain antibodies into MMR defective cells from any tissue of the MMR defective animal.

[0052] Once a transfected cell line or a colony of transgenic animals has been produced, it can be used to generate new mutations in one or more gene(s) of interest. A gene of interest can be any gene naturally possessed by the cell line or transgenic animal or introduced into the cell line or transgenic animal. An advantage of using such cells or animals to induce mutations is that the cell or animal need not be exposed to mutagenic chemicals or radiation, which may have secondary harmful effects, both on the object of the exposure and on the workers. However, chemical mutagens may be used in combination with MMR deficiency, which renders such mutagens less toxic due to an undetermined mechanism. Hypermutable animals can then be bred and selected for those producing genetically variable B-cells that may be isolated and cloned to identify new cell lines that are useful for producing genetically variable cells. Once a new trait is identified, the dominant negative MMR gene allele can be removed by directly knocking out the allele by technologies used by those skilled in the art or by breeding to mates lacking the dominant negative allele to select for offspring with a desired trait and a stable genome. Another alternative is to use a CRE-LOX expression system, whereby the dominant negative allele is spliced from the animal genome once an animal containing a genetically diverse immunoglobulin profile has been established. Yet another alternative is the use of inducible vectors such as the steroid induced pIND (Invitrogen) or pMAM (Clonetech) vectors which express exogenous genes in the presence of corticosteroids.

[0053] Mutations can be detected by analyzing for alterations in the genotype of the cells or animals, for example by examining the sequence of genomic DNA, cDNA, messenger RNA, or amino acids associated with the gene of interest. Mutations can also be detected by screening for the production of antibody titers. A mutant polypeptide can be detected by identifying alterations in electrophoretic mobility, spectroscopic properties, or other physical or structural characteristics of a protein encoded by a mutant gene. One can also screen for altered function of the protein *in situ*, in isolated form, or in model systems. One can screen for alteration of any property of the cell or animal associated with the function of the gene of interest, such as but not limited to Ig secretion.

[0054] Cells expressing the dominant negative alleles can be “cured” in that the dominant negative allele can be turned off, if inducible, eliminated from the cell, and the like such that the cells become genetically stable once more and no longer accumulate mutations at the abnormally high rate. The polynucleotide can be cloned into an expression vector containing constitutively active promoter segment (such as but not limited to CMV, SV40, Elongation Factor or LTR sequences) or to inducible promoter sequences such as the steroid inducible pIND vector where the expression of the dominant negative mismatch repair gene can be regulated. The cDNA is introduced into the cell by transfection. Upon identification of the desired phenotype or trait the organism can then be genetically stabilized.

[0055] Examples of mismatch repair proteins and nucleic acid sequences include mouse PMS2 (SEQ ID NOs:5 and 6), human PMS2 (SEQ ID NOs:7 and 8), human PMS1 (SEQ ID NOs:9 and 10), human MSH2 (SEQ ID NOs: 11 and 12), human MLH1 (SEQ ID NOs:13 and 14), and human PMS2-134 (SEQ ID NOs:15 and 16).

[0056] Mutant antibodies showing increased affinity for antigen were sequenced and compared to the sequence of the wild-type (WT) H36 parental antibody. It has been discovered that alterations of amino acids to proline has the effect of increasing affinity for antigen when introduced into the variable region of either the light chain or heavy chain of the immunoglobulin molecule. While not wishing to be bound by any particular theory of operation, it is believed that the prolines introduce a localized area of rigidity and lend stability to the immunoglobulin molecule, particularly to the regions around the antigen combining sites.

[0057] Thus, the invention provides for a method to increase the affinity of antibodies comprising replacing amino acids of the variable domain heavy and/or light chain with proline or hydroxyproline (collectively referred to as “proline”). In some embodiments, the substitution of prolines is in the heavy chain variable domain. In some embodiments, the substitution of prolines is in the light chain variable domain. In other embodiments, the substitution of proline is in both the heavy chain and the light chain of the variable domain of the immunoglobulin molecule. In some embodiments, the proline substitutes for another amino acid having a non-polar sidechain (e.g., glycine, alanine, valine, leucine, isoleucine, phenylalanine, methionine, tryptophan and cysteine). In some embodiments, further exchanges of amino acids having non-polar sidechains with other amino acids having non-polar sidechains may also confer increased affinity of the antibody for the antigen. In some embodiments, the amino acid substitutions are in a framework region of the heavy chain. In other embodiments, the amino acid substitutions are in a framework region of the light chain.

[0058] In other embodiments, the amino acid substitutions are in a framework region of both the heavy and light chain. In some embodiments, the amino acid substitutions are in the first framework region (FR1) of the heavy chain. In other embodiments, the amino acid substitution is in the second framework region (FR2) of the heavy chain. In other embodiments, the amino acid substitution is in the third framework region (FR3) of the heavy chain. In other embodiments, the amino acid substitution is in the fourth framework region (FR4) of the heavy chain. In some embodiments, the amino acid substitutions are in the first framework region (FR1) of the light chain. In other embodiments, the amino acid substitution is in the second framework region (FR2) of the light chain. In other embodiments, the amino acid substitution is in the third framework region (FR3) of the light chain. In other embodiments, the amino acid substitution is in the fourth framework region (FR4) of the light chain.

[0059] In certain embodiments of the invention, a proline substitutes for an alanine at position 6 of SEQ ID NO:18. In other embodiments, proline substitutes for alanine at position 6 of SEQ ID NO: 18 and the glycine at position 9 of SEQ ID NO:18, and/or the lysine at position 10 of SEQ ID NO:18 is substituted with an amino acid having a non-polar side chain (preferably, valine and arginine, respectively). In other embodiments, proline substitutes for leucine at position 22 of SEQ ID NO:21.

[0060] The recent clinical and commercial success of anticancer antibodies, such as rituximab (Rituxan) and trastuzumab (Herceptin) and small molecule signal transduction inhibitors such as imatinib mesylate, (Gleevec or STI-571), has created great interest in “targeted” therapeutics for hematopoietic malignancies and solid tumors. In comparison to small molecule cytotoxic agents it is hoped that these approaches will result in lower toxicity while maintaining or increasing the therapeutic efficacy.

[0061] Antibodies conjugated to radionuclides, drugs or toxins have intrinsic specificity due to their specific antigen binding. The degree of specificity is dependent on the relative specificity of the antigen on the targeted tumor. The conjugated toxic component complicates the approach since the radionuclide is irradiating normal tissues during the duration of its circulation (prolonged for a humanized antibody) and drugs and toxins can be detached from the antibody by enzymatic and non-enzymatic mechanism, thus delivering the toxin to normal tissue. In addition, the presence of the conjugate can result in the body recognizing the complex as foreign with the resulting uptake into organs of clearance such as the liver.

[0062] Previous attempts at maximizing the therapeutic potential of monoclonal antibodies have mostly focused on improving the affinity and avidity of binding to the targeted antigen. The method of the invention allows for the maximization of efficacy of an unconjugated

antibody. It is an object of the invention to generate improved monoclonal antibodies (*e.g.*, humanized antibodies) by producing and assaying molecules with increases in the effector function (Fc) of the protein, regardless of the mechanisms behind the increases. These new molecules could then target human tumors and have enhanced potency for tumor cell killing. The resulting product would be expected to function at a lower dose, without an increase in toxicity, thus increasing its therapeutic window. In addition, many previous studies have shown that the accretion of an antibody into a tumor is relatively low (Sands, H. *Cancer Research* (Suppl) 1990, 50: 809s-813s). An increase in effector function could result in an increased therapeutic efficacy thus allowing a humanized monoclonal antibody to have a therapeutic effect at the accretion rates found in human tumors.

[0063] The method of the invention can enhance the effector function of monoclonal antibodies, including, but not limited to those currently in development for the treatment of cancer. Glycosylation is only one of many ways in which antibody effector function can be manipulated. The technology is ideally suited for this study since it can yield a more potent antibody that has minimal changes in amino acid sequence, in the glycosylation pattern and/or in other known and unknown mechanisms. These changes may arise due to genetic changes in the DNA resulting in the amino acid sequence of the immunoglobulin molecule itself, or in the cellular machinery that controls the sequence or nature of the post translational pattern.

[0064] The method of the invention may be used to enhance properties of antibodies, including, but not limited to, rodent antibodies against therapeutic targets, and chimerized and humanized versions thereof. One such antibody, referred to as MORAb-03, binds to a cell surface adult-type, high-affinity folate-binding glycoprotein antigen (designated MORAb-03 antigen) of normal placenta and gestational choriocarcinomas. Expression profiles show that MORAb-03 antigen has a restricted distribution in normal tissues, being expressed primarily in a subset of simple epithelia (Rettig WJ, Cordon-Cardo C, Koulos JP, Lewis JL Jr, Oettgen HF, Old U. *Int J Cancer*. 1985 Apr 15;35(4):469-75; Coney LR, Tomassetti A, Carayannopoulos L, Frasca V, Kamen BA, Colnaghi MI, Zurawski VR Jr. *Cancer Res*. 1991 Nov 15;51(22):6125-32) and fresh frozen sections of human pancreas, proximal kidney tubules, and bronchi. The distribution of MORAb-03 antigen was further determined by immunohistochemical analysis of 150 tumor cell lines and normal cell cultures as well as on primary tumor tissues using a MORAb-03-antigen specific mouse derived monoclonal antibody (L-26). MORAb-03 antigen was found expressed on all cultured choriocarcinomas and teratocarcinomas. Immunohistochemistry of primary tumors found MORAb-03 antigen expression in a significant number of ovarian tumors and over 400 tumors of other histological types (Garin-Chesa P,

Campbell I, Saigo PE, Lewis JL Jr, Old U, Rettig WJ. *Am J Pathol.* 1993 Feb; 142(2) :557-67). Ovarian carcinomas derived from coelomic epithelium showed the most consistent and strongest immunostaining with the MORAb-03 antibody, with 52 of 56 cases being MORAb-03 positive. MORAb-03 antigen was not detected in normal fetal or adult ovary; however, it was found present in the lining epithelia in a subset of benign ovarian cysts.

[0065] The method of the invention may be used to develop a production line that produces an antibody that can meet the therapeutic and manufacturing requirements (*i.e.*, high affinity and production) specified by the current industry standards. The method of the invention is suitable for application to mAbs generated using standard murine hybridoma techniques. In some embodiments, murine complementary determining regions (CDRs) are grafted into a human IgG1k backbone, and the light and heavy chain cDNAs are transfected into NS0 cells, resulting in the generation of an antibody production system known in the industry as “transfectoma.” The process of grafting the CDRs into a human immunoglobulin sequence is called “humanization.” Unfortunately, the transfectoma line produced the MORAb-03 at a rate of less than 1 pg/cell/day and the humanization process had led to a reduction of the affinity, now in the micromolar range. The method of the invention enabled successful production of an optimized, humanized MORAb-03 antibody with acceptable antigen binding activity (low nanomolar dissociation constant) and production rates (>10 pg/cell/day). ADCC assays using human ovarian cancer cells as target and peripheral blood mononuclear cells (PBMCs) as effector cells showed that 200 ng/ml of MORAb-03 produced in NS0 cells was able to mediate the lysis of 44% of target cells, whereas lysis mediated by the control IgG1 antibody was only 6% (**Figure 7**). In contrast, the same concentration of MORAb-03 produced in CHO cells mediated the lysis of 32% of target cells, a reduction of 27% (paired T test = 0.0008) (**Figure 4**). Multiple independent ADCC assays have shown a similar trend, where MORAb-03 CHO produced in cells showed a reduction in activity as high as 50% compared to MORAb-03 produced in NSO cells. CHO is a standard host cell line recognized by the FDA and is well characterized by contract manufacturing organizations. Among its strengths are the robustness and stability of its growth, its adaptability to different manufacturing schemes and serum-free media, and its high efficiency and reproducibility of antibody production. A CHO line producing MORAb-03 with ADCC activity similar to or higher than NS0 cell-produced MORAb-03 will be an extremely valuable manufacturing asset for the production of a therapeutic anti-cancer biologic. The method of the invention may be applied to the cell lines producing MORAb-03 in order to identify variants producing antibodies with enhanced ADCC activity.

[0066] In summary, the MORAb-03 antigen is a glycoprotein whose expression is highly restricted in normal tissues and highly expressed in a large portion of ovarian tumors. The antibody is capable of inducing ADCC thus making it an excellent drug candidate for the treatment of ovarian of cancer.

[0067] For further information on the background of the invention the following references may be consulted, each of which is incorporated herein by reference in its entirety:

1. Glaser, V. (1996) Can ReoPro repolish tarnished mono clonal therapeutics? *Nat. Biotechnol.* 14:1216-1217.
2. Weiner, L.M. (1999) Monoclonal antibody therapy of cancer. *Semin. Oncol.* 26:43-51.
3. Saez-Llorens, X.E. *et al.* (1998) Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. *Pediat. Infect. Dis. J.* 17:787-791.
4. Shield, C.F. *et al.* (1996) A cost-effective analysis of OKT3 induction therapy in cadaveric kidney transplantation. *Am. J. Kidney Dis.* 27:855-864.
5. Kbazaeli, M.B. *et al.* (1994) Human immune response to monoclonal antibodies. *J. Immunother.* 15:42-52.
6. Emery, S.C. and W.J. Harris "Strategies for humanizing antibodies" In: ANTIBODY ENGINEERING C.A.K. Borrebaeck (Ed.) Oxford University Press, N.Y. 1995, pp. 159-183.
7. U.S. Patent No. 5,530,101 to Queen and Selick.
8. Reff, M.E. (1993) High-level production of recombinant immunoglobulins in mammalian cells. *Curr. Opin. Biotechnol.* 4:573-576.
9. Neuberger, M. and M. Gruggermann, (1997) Monoclonal antibodies. Mice perform a human repertoire. *Nature* 386:25-26.
10. Fiedler, U. and U. Conrad (1995) High-level production and long-term storage of engineered antibodies in transgenic tobacco seeds. *Bio/Technology* 13:1090-1093.
11. Baker S.M. *et al.* (1995) Male defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis. *Cell* 82:309-319.
12. Bronner, C.E. *et al.* (1994) Mutation in the DNA mismatch repair gene homologue *hMLH1* is associated with hereditary non-polyposis colon cancer. *Nature* 368:258-261.

13. de Wind N. *et al.* (1995) Inactivation of the mouse *Msh2* gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. *Cell* 82:321-330.
14. Drummond, J.T. *et al.* (1995) Isolation of an hMSH2-p160 heterodimer that restores mismatch repair to tumor cells. *Science* 268:1909-1912.
15. Modrich, P. (1994) Mismatch repair, genetic stability, and cancer. *Science* 266:1959-1960.
16. Nicolaides, N.C. *et al.* (1998) A Naturally Occurring hPMS2 Mutation Can Confer a Dominant Negative Mutator Phenotype. *Mol. Cell. Biol.* 18:1635-1641.
17. Prolla, T.A. *et al.* (1994) MLH1, PMS1, and MSH2 Interaction during the initiation of DNA mismatch repair in yeast. *Science* 264:1091-1093.
18. Strand, M. *et al.* (1993) Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair. *Nature* 365:274-276.
19. Su, S.S., R.S. Lahue, K.G. Au, and P. Modrich (1988) Mismatch specificity of methyl directed DNA mismatch corrections *in vitro*. *J. Biol. Chem.* 263 :6829-6835.
20. Parsons, R. *et al.* (1993) Hypermutability and mismatch repair deficiency in RER+ tumor cells. *Cell* 75:1227-1236.
21. Papadopoulos, N. *et al.* (1993) Mutation of a mutL homolog is associated with hereditary colon cancer. *Science* 263:1625-1629.
22. Perucho, M. (1996) Cancer of the microsatellite mutator phenotype. *Biol. Chem.* 377:675-684.
23. Nicolaides N.C., K.W. Kinzler, and B. Vogelstein (1995) Analysis of the 5' region of PMS2 reveals heterogenous transcripts and a novel overlapping gene. *Genomics* 29:329-334.
24. Nicolaides, N.C. *et al.* (1995) Genomic organization of the human PMS2 gene family. *Genomics* 30:195-206.
25. Palombo, F. *et al.* (1994) Mismatch repair and cancer. *Nature* 36:417.
26. Eshleman J.R. and S.D. Markowitz (1996) Mismatch repair defects in human carcinogenesis. *Hum. Mol. Genet.* 5:1489-494.
27. Liu, T. *et al.* (2000) Microsatellite instability as a predictor of a mutation in a DNA mismatch repair gene in familial colorectal cancer. *Genes Chromosomes Cancer* 27:17-25.
28. Nicolaides, N.C. *et al.* (1992) The Jun family members, c-JUN and JUND, transactivate the human c-myc promoter via an Ap1 like element. *J. Biol. Chem.* 267:19665-19672.

29. Shields, R.L. *et al.* (1995) Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release. *Int. Arch. Allergy Immunol.* 107:412-413.
30. Frigerio L. *et al.* (2000) Assembly, secretion, and vacuolar delivery of a hybrid immunoglobulin in plants. *Plant Physiol.* 123:1483-1494.
31. Bignami M, (2000) Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. *Mutat. Res.* 462:71-82.
32. Drummond, J.T. *et al.* (1996) Cisplatin and adriamycin resistance are associated with MutLa and mismatch repair deficiency in an ovarian tumor cell line. *J. Biol. Chem.* 271:19645-19648.
33. Galio, L. *et al.* (1999) ATP hydrolysis-dependent formation of a dynamic ternary nucleoprotein complex with MutS and MutL. *Nucl. Acids Res.* 27:2325-2331.

[0068] The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for purposes of illustration only, and are not intended to limit the scope of the invention.

#### **EXAMPLE I: Stable expression of dominant negative MMR genes in hybridoma cells**

[0069] It has been previously shown by Nicolaides *et al.* (Nicolaides *et al.* (1998) A Naturally Occurring hPMS2 Mutation Can Confer a Dominant Negative Mutator Phenotype *Mol. Cell. Biol.* 18:1635-1641) that the expression of a dominant negative allele in an otherwise MMR proficient cell could render these host cells MMR deficient. The creation of MMR deficient cells can lead to the generation of genetic alterations throughout the entire genome of a host organisms offspring, yielding a population of genetically altered offspring or siblings that may produce biochemicals with altered properties. This patent application teaches of the use of dominant negative MMR genes in antibody-producing cells, including but not limited to rodent hybridomas, human hybridomas, chimeric rodent cells producing human immunoglobulin gene products, human cells expressing immunoglobulin genes, mammalian cells producing single chain antibodies, and prokaryotic cells producing mammalian immunoglobulin genes or chimeric immunoglobulin molecules such as those contained within single-chain antibodies. The cell expression systems described above that are used to produce antibodies are well known by those skilled in the art of antibody therapeutics.

[0070] To demonstrate the ability to create MMR defective hybridomas using dominant negative alleles of MMR genes, we first transfected a mouse hybridoma cell line that is known to



produce an antibody directed against the human IgE protein with an expression vector containing the human PMS2 (cell line referred to as HBPMS2), the previously published dominant negative PMS2 mutant referred herein as PMSI34 (cell line referred to as HB134), or with no insert (cell line referred to as HBvec). The results showed that the PMSI34 mutant could indeed exert a robust dominant negative effect, resulting in biochemical and genetic manifestations of MMR deficiency. Unexpected was the finding that the full length PMS2 also resulted in a lower MMR activity while no effect was seen in cells containing the empty vector. A brief description of the methods is provided below.

[0071] The MMR proficient mouse H36 hybridoma cell line was transfected with various hPMS2 expression plasmids plus reporter constructs for assessing MMR activity. The MMR genes were cloned into the pEF expression vector, which contains the elongation factor promoter upstream of the cloning site followed by a mammalian polyadenylation signal. This vector also contains the NEO<sup>r</sup> gene that allows for selection of cells retaining this plasmid. Briefly, cells were transfected with 1 µg of each vector using polyliposomes following the manufacturer's protocol (Life Technologies). Cells were then selected in 0.5 mg/ml of G418 for 10 days and G418 resistant cells were pooled together to analyze for gene expression. The pEF construct contains an intron that separates the exon 1 of the EF gene from exon 2, which is juxtaposed to the 5' end of the polylinker cloning site. This allows for a rapid reverse transcriptase polymerase chain reaction (RT-PCR) screen for cells expressing the spliced products. At day 17, 100,000 cells were isolated and their RNA extracted using the trizol method as previously described (Nicolaidis N.C., Kinzler, K.W., and Vogelstein, 8. (1995) Analysis of the 5' region of PMS2 reveals heterogeneous transcripts and a novel overlapping gene. *Genomics* 29:329-334). RNAs were reverse transcribed using Superscript II (Life Technologies) and PCR amplified using a sense primer located in exon 1 of the EF gene (5'-ttt cgc aac ggg ttt gcc g-3') (SEQ ID NO:23) and an antisense primer (5'-gtt tca gag tta agc ctt cg-3') (SEQ ID NO:24) centered at nt 283 of the published human PMS2 cDNA, which will detect both the full length as well as the PMSI34 gene expression. Reactions were carried out using buffers and conditions as previously described (Nicolaidis, N.C., *et al.* (1995) Genomic organization of the human PMS2 gene family. *Genomics* 30:195-206), using the following amplification parameters: 94°C for 30 sec, 52°C for 2 min, 72°C for 2 min, for 30 cycles. Reactions were analyzed on agarose gels. Figure 1 shows a representative example of PMS expression in stably transduced H36 cells.

[0072] Expression of the protein encoded by these genes were confirmed via western blot using a polyclonal antibody directed to the first 20 amino acids located in the N-terminus of the protein following the procedures previously described (data not shown) (Nicolaidis *et al.*

(1998) A Naturally Occurring hPMS2 Mutation Can Confer a Dominant Negative Mutator Phenotype. *Mol. Cell. Biol.* 18:1635-1641).

**EXAMPLE 2: hPMS134 Causes a Defect in MMR Activity and hypermutability in hybridoma cells**

[0073] A hallmark of MMR deficiency is the generation of unstable microsatellite repeats in the genome of host cells. This phenotype is referred to as microsatellite instability (MI) (Modrich, P. (1994) Mismatch repair, genetic stability, and cancer. *Science* 266:1959-1960; Palombo, F., *et al.* (1994) Mismatch repair and cancer. *Nature* 36:4 17). MI consists of deletions and/or insertions within repetitive mono-, di-, and/or tri-nucleotide repetitive sequences throughout the entire genome of a host cell. Extensive genetic analyses of eukaryotic cells have found that the only biochemical defect that is capable of producing MI is defective MMR (Strand, M., *et al.* (1993) Destabilization of tracts of simple repetitive DNA in yeast by mutations affecting DNA mismatch repair. *Nature* 365:274-276; Perucho, M. (1996) Cancer of the microsatellite mutator phenotype. *Biol Chem.* 377:675-684; Eshleman J.R., and Markowitz, S.D. (1996) Mismatch repair defects in human carcinogenesis. *Hum. Mol. Genet.* 5:1489-494). In light of this unique feature that defective MMR has on promoting MI, it is now used as a biochemical marker to survey for lack of MMR activity within host cells (Perucho, M. (1996) Cancer of the microsatellite mutator phenotype. *Biol Chem.* 377:675-684; Eshleman J.R., and Markowitz, S.D. (1996) Mismatch repair defects in human carcinogenesis. *Hum. Mol. Genet.* 5:1489-494; Liu, T., *et al.* (2000) Microsatellite instability as a predictor of a mutation in a DNA mismatch repair gene in familial colorectal cancer. *Genes Chromosomes Cancer* 27:17-25).

[0074] A method used to detect MMR deficiency in eukaryotic cells is to employ a reporter gene that has a polynucleotide repeat inserted within the coding region that disrupts its reading frame due to a frameshift. In the case where MMR is defective, the reporter gene will acquire random mutations (*i.e.*, insertions and/or deletions) within the polynucleotide repeat yielding clones that contain a reporter with an open reading frame. We have employed the use of an MMR-sensitive reporter gene to measure for MMR activity in HBvec, HBPMS2, and HBPMS 134 cells. The reporter construct used the pCAR-OF, which contains a hygromycin resistance (HYG) gene plus a  $\beta$ -galactosidase gene containing a 29 bp out-of-frame poly-CA tract at the 5' end of its coding region. The pCAR-OF reporter would not generate  $\beta$ -galactosidase activity unless a frame-restoring mutation (*i.e.*, insertion or deletion) arose following transfection. HBvec, HBPMS2, and HB134 cells were each transfected with pCAR-OF vector in duplicate reactions following the protocol described in Example 1. Cells were

selected in 0.5 mg/ml G418 and 0.5mg/ml HYG to select for cells retaining both the MMR effector and the pCAR-OF reporter plasmids. All cultures transfected with the pCAR vector resulted in a similar number of HYG/G418 resistant cells. Cultures were then expanded and tested for  $\beta$ -galactosidase activity *in situ* as well as by biochemical analysis of cell extracts. For *in situ* analysis, 100,000 cells were harvested and fixed in 1% glutaraldehyde, washed in phosphate buffered saline solution and incubated in 1 ml of X-gal substrate solution [0.15 M NaCl, 1 mM MgCl<sub>2</sub>, 3.3 mM K<sub>4</sub>Fe(CN)<sub>6</sub>, 3.3 mM K<sub>3</sub>Fe(CN)<sub>6</sub>, 0.2% X-Gal] in 24 well plates for 2 hours at 37°C. Reactions were stopped in 500 mM sodium bicarbonate solution and transferred to microscope slides for analysis. Three fields of 200 cells each were counted for blue ( $\beta$ -galactosidase positive cells) or white ( $\beta$ -galactosidase negative cells) to assess for MMR inactivation. Table 1 shows the results from these studies. While no  $\beta$ -galactosidase positive cells were observed in HBvec cells, 10% of the cells per field were  $\beta$ -galactosidase positive in HB 134 cultures and 2% of the cells per field were  $\beta$ -galactosidase positive in HBPMS2 cultures.

[0075] Cell extracts were prepared from the above cultures to measure  $\beta$ -galactosidase using a quantitative biochemical assay as previously described (Nicolaidis *et al.* (1998) A Naturally Occurring hPMS2 Mutation Can Confer a Dominant Negative Mutator Phenotype *Mol. Cell. Biol.* 18:1635-1641; Nicolaidis, N.C., *et al.* (1992) The Jun family members, c-JUN and JUND, transactivate the human c-myc promoter via an Ap1 like element. *J. Biol. Chem.* 267:19665-19672). Briefly, 100,000 cells were collected, centrifuged and resuspended in 200  $\mu$ l of 0.25M Tris, pH 8.0. Cells were lysed by freeze/thawing three times and supernatants collected after microfugation at 14,000 rpms to remove cell debris. Protein content was determined by spectrophotometric analysis at OD<sup>280</sup>. For biochemical assays, 20  $\mu$ g of protein was added to buffer containing 45 mM 2-mercaptoethanol, 1mM MgCl<sub>2</sub>, 0.1 M NaPO<sub>4</sub> and 0.6 mg/ml Chlorophenol red- $\beta$ -D-galactopyranoside (CPRG, Boehringer Mannheim). Reactions were incubated for 1 hour, terminated by the addition of 0.5 M Na<sub>2</sub>CO<sub>3</sub>, and analyzed by spectrophotometry at 576 nm. H36 cell lysates were used to subtract out background. Figure 2 shows the  $\beta$ -galactosidase activity in extracts from the various cell lines. As shown, the HB134 cells produced the highest amount of  $\beta$ -galactosidase, while no activity was found in the HBvec cells containing the pCAR-OF. These data demonstrate the ability to generate MMR defective hybridoma cells using dominant negative MMR gene alleles.

Table 1.  $\beta$ -galactosidase expression of HBvec, HBPMS2 and HB134 cells transfected with pCAR-OF reporter vectors. Cells were transfected with the pCAR-OF  $\beta$ -galactosidase reporter plasmid. Transfected cells were selected in hygromycin and G418, expanded and stained with X-gal solution to measure for  $\beta$ -galactosidase activity (blue colored cells). 3 fields of 200 cells each were

analyzed by microscopy. The results below represent the mean +/- standard deviation of these experiments.

Cell line	Number Blue Cells
HBvec	0 +/- 0
HBPMS2	4 +/- 1
HB134	20 +/- 3

**EXAMPLE 3: Screening strategy to identify hybridoma clones producing antibodies with higher binding affinities and/or increased immunoglobulin production.**

[0076] An application of the methods presented within this document is the use of MMR deficient hybridomas or other immunoglobulin producing cells to create genetic alterations within an immunoglobulin gene that will yield antibodies with altered biochemical properties. An illustration of this application is demonstrated within this example whereby the HB134 hybridoma (Example 1), which is a MMR-defective cell line that produces an anti-human immunoglobulin type E (hIgE) MAb, is grown for 20 generations and clones are isolated in 96-well plates and screened for hIgE binding. Figure 3 outlines the screening procedure to identify clones that produce high affinity MAbs, which is presumed to be due to an alteration within the light or heavy chain variable region of the protein. The assay employs the use of a plate Enzyme Linked Immunosorbant Assay (ELISA) to screen for clones that produce high-affinity MAbs. 96-well plates containing single cells from HBvec or HB134 pools are grown for 9 days in growth medium (RPMI 1640 plus 10% fetal bovine serum) plus 0.5 mg/ml G418 to ensure clones retain the expression vector. After 9 days, plates are screened using an hIgE plate ELISA, whereby a 96 well plate is coated with 50  $\mu$ ls of a 1  $\mu$ g/ml hIgE solution for 4 hours at 4°C. Plates are washed 3 times in calcium and magnesium free phosphate buffered saline solution (PBS<sup>-/-</sup>) and blocked in 100  $\mu$ ls of PBS<sup>-/-</sup> with 5% dry milk for 1 hour at room temperature. Wells are rinsed and incubated with 100  $\mu$ ls of a PBS solution containing a 1:5 dilution of conditioned medium from each cell clone for 2 hours. Plates are then washed 3 times with PBS<sup>-/-</sup> and incubated for 1 hour at room temperature with 50  $\mu$ ls of a PBS<sup>-/-</sup> solution containing 1:3000 dilution of a sheep anti-mouse horse radish peroxidase (HRP) conjugated secondary antibody. Plates are then washed 3 times with PBS<sup>-/-</sup> and incubated with 50  $\mu$ ls of TMB-HRP substrate (BioRad) for 15 minutes at room temperature to detect amount of antibody produced by each clone. Reactions are stopped by adding 50  $\mu$ ls of 500mM sodium bicarbonate and analyzed by OD at 415nm using a BioRad plate reader. Clones exhibiting an enhanced signal over background cells (H36 control cells) are then isolated and expanded into 10 ml cultures for

additional characterization and confirmation of ELISA data in triplicate experiments. ELISAs are also performed on conditioned (CM) from the same clones to measure total Ig production within the conditioned medium of each well. Clones that produce an increased ELISA signal and have increased antibody levels are then further analyzed for variants that over-express and/or over-secrete antibodies as described in Example 4. Analysis of five 96-well plates each from HBvec or HB 134 cells have found that a significant number of clones with a higher Optical Density (OD) value is observed in the MMR-defective HB134 cells as compared to the HBvec controls. Figure 4 shows a representative example of HB134 clones producing antibodies that bind to specific antigen (in this case IgE) with a higher affinity. Figure 4 provides raw data from the analysis of 96 wells of HBvec (left graph) or HB134 (right graph) which shows 2 clones from the HB134 plate to have a higher OD reading due to 1) genetic alteration of the antibody variable domain that leads to an increased binding to IgE antigen, or 2) genetic alteration of a cell host that leads to over-production/secretion of the antibody molecule. Anti-Ig ELISA found that the two clones, shown in Figure 4 have Ig levels within their CM similar to the surrounding wells exhibiting lower OD values. These data suggest that a genetic alteration occurred within the antigen binding domain of the antibody which in turn allows for higher binding to antigen.

[0077] Clones that produced higher OD values as determined by ELISA were further analyzed at the genetic level to confirm that mutations within the light or heavy chain variable region have occurred that lead to a higher binding affinity hence yielding a stronger ELISA signal. Briefly, 100,000 cells are harvested and extracted for RNA using the Triazol method as described above. RNAs are reverse transcribed using Superscript II as suggested by the manufacturer (Life Technology) and PCR amplified for the antigen binding sites contained within the variable light and heavy chains. Because of the heterogeneous nature of these genes, the following degenerate primers are used to amplify light and heavy chain alleles from the parent H36 strain.

Light chain sense: 5'-GGA TTT TCA GGT GCA GAT TTT CAG-3' (SEQ ID NO:1)

Light chain antisense: 5'-ACT GGA TGG TGG GAA GAT GGA-3' (SEQ ID NO:2)

Heavy chain sense: 5'-A(G/T) GTN (A/C)AG CTN CAG (C/G)AG TC-3'  
(SEQ ID NO:3)

Heavy chain antisense: 5'-TNC CTT G(A/G)C CCC AGT A(G/A)(A/T)C-3'  
(SEQ ID NO:4)

[0078] PCR reactions using degenerate oligonucleotides are carried out at 94°C for 30 sec, 52°C for 1 min, and 72°C for 1 min for 35 cycles. Products are analyzed on agarose gels.

Products of the expected molecular weights are purified from the gels by Gene Clean (Bio 101), cloned into T-tailed vectors, and sequenced to identify the wild type sequence of the variable light and heavy chains. Once the wild type sequence has been determined, nondegenerate primers were made for RT-PCR amplification of positive HB134 clones. Both the light and heavy chains were amplified, gel purified and sequenced using the corresponding sense and antisense primers. The sequencing of RT-PCR products gives representative sequence data of the endogenous immunoglobulin gene and not due to PCR-induced mutations. Sequences from clones were then compared to the wild type sequence for sequence comparison. An example of the ability to create *in vivo* mutations within an immunoglobulin light or heavy chain is shown in figure 5, where HB134 clone92 was identified by ELISA to have an increased signal for hIgE. The light chain was amplified using specific sense and antisense primers. The light chain was RT-PCR amplified and the resulting product was purified and analyzed on an automated ABI377 sequencer. As shown in clone A, a residue -4 upstream of the CDR region 3 had a genetic change from ACT to TCT, which results in a Thr to Ser change within the framework region just preceding the CDR#3. In clone B, a residue -6 upstream of the CDR region had a genetic change from CCC to CTC, which results in a Pro to Leu change within framework region preceding CDR#2.

[0079] The ability to generate random mutations in immunoglobulin genes or chimeric immunoglobulin genes is not limited to hybridomas. Nicolaides *et al.* (Nicolaides *et al.* (1998) A Naturally Occurring hPMS2 Mutation Can Confer a Dominant Negative Mutator Phenotype *Mol. Cell. Biol.* 18:1635-1641) has previously shown the ability to generate hypermutable hamster cells and produce mutations within an endogenous gene. A common method for producing humanized antibodies is to graft CDR sequences from a MAb (produced by immunizing a rodent host) onto a human Ig backbone, and transfection of the chimeric genes into Chinese Hamster Ovary (CHO) cells which in turn produce a functional Ab that is secreted by the CHO cells (Shields, R.L., *et al.* (1995) Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release. *Int Arch. Allergy Immunol.* 107:412-413). The methods described within this application are also useful for generating genetic alterations within Ig genes or chimeric Igs transfected within host cells such as rodent cell lines, plants, yeast and prokaryotes (Frigerio L, *et al.* (2000) Assembly, secretion, and vacuolar delivery of a hybrid immunoglobulin in plants. *Plant Physiol.* 123:1483-1494).

[0080] These data demonstrate the ability to generate hypermutable hybridomas, or other Ig producing host cells that can be grown and selected, to identify structurally altered immunoglobulins yielding antibodies with enhanced biochemical properties, including but not

limited to increased antigen binding affinity. Moreover, hypermutable clones that contain missense mutations within the immunoglobulin gene that result in an amino acid change or changes can be then further characterized for *in vivo* stability, antigen clearance, on-off binding to antigens, *etc.* Clones can also be further expanded for subsequent rounds of *in vivo* mutations and can be screened using the strategy listed above.

**[0081]** The use of chemical mutagens to produce genetic mutations in cells or whole organisms is limited due to the toxic effects that these agents have on “normal” cells. The use of chemical mutagens such as MNU in MMR defective organisms is much more tolerable yielding to a 10 to 100 fold increase in genetic mutation over MMR deficiency alone (Bignami M, (2000) Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. *Mutat. Res.* 462:71-82). This strategy allows for the use of chemical mutagens to be used in MMR-defective Ab producing cells as a method for increasing additional mutations within immunoglobulin genes or chimeras that may yield functional Abs with altered biochemical properties such as enhanced binding affinity to antigen, *etc.*

#### **Example 4: Generation of antibody producing cells with enhanced antibody production**

**[0082]** Analysis of clones from H36 and HB134 following the screening strategy listed above has identified a significant number of clones that produce enhanced amounts of antibody into the medium. While a subset of these clones gave higher Ig binding data as determined by ELISA as a consequence of mutations within the antigen binding domains contained in the variable regions, others were found to contain “enhanced” antibody production. A summary of the clones producing enhanced amounts of secreted MAbs is shown in TABLE 2, where a significant number of clones from HB134 cells were found to produce enhanced Ab production within the conditioned medium as compared to H36 control cells.

TABLE 2. Generation of hybridoma cells producing high levels of antibody. HB134 clones were assayed by ELISA for elevated Ig levels. Analysis of 480 clones showed that a significant number of clones had elevated MAb product levels in their CM. Quantification showed that several of these clones produced greater than 500 ngs/ml of MAb due to either enhanced expression and/or secretion as compared to clones from the H36 cell line.

Cell Line	% clones > 400 ng/ml	% clones > 500 ng/ml
H36	1/480 = 0.2%	0/480 = 0%
HB134	50/480 = 10%	8/480 = 1.7%

[0083] Cellular analysis of HB134 clones with higher MAb levels within the conditioned medium (CM) were analyzed to determine if the increased production was simply due to genetic alterations at the Ig locus that may lead to over-expression of the polypeptides forming the antibody, or due to enhanced secretion due to a genetic alteration affecting secretory pathway mechanisms. To address this issue, three HB134 clones that had increased levels of antibody within their CM were expanded. 10,000 cells were prepared for western blot analysis to assay for intracellular steady state Ig protein levels (Figure 6). In addition, H36 cells were used as a standard reference (Lane 2) and a rodent fibroblast (Lane 1) was used as an Ig negative control. Briefly, cells were pelleted by centrifugation and lysed directly in 300 µl of SDS lysis buffer (60 mM Tris, pH 6.8, 2% SDS, 10% glycerol, 0.1 M 2-mercaptoethanol, 0.001 % bromophenol blue) and boiled for 5 minutes. Lysate proteins were separated by electrophoresis on 4-12% NuPAGE gels (for analysis of Ig heavy chain). Gels were electroblotted onto Immobilon-P (Millipore) in 48 mM Tris base, 40 mM glycine, 0.0375% SDS, 20% methanol and blocked at room temperature for 1 hour in Tris-buffered saline (TBS) plus 0.05 % Tween-20 and 5 % condensed milk. Filters were probed with a 1:10,000 dilution of sheep anti-mouse horseradish peroxidase conjugated monoclonal antibody in TBS buffer and detected by chemiluminescence using Supersignal substrate (Pierce). Experiments were repeated in duplicates to ensure reproducibility. Figure 6 shows a representative analysis where a subset of clones had enhanced Ig production which accounted for increased Ab production (Lane 5) while others had a similar steady state level as the control sample, yet had higher levels of Ab within the CM. These data suggest a mechanism whereby a subset of HB134 clones contained a genetic alteration that in turn produces elevated secretion of antibody.

[0084] The use of chemical mutagens to produce genetic mutations in cells or whole organisms is limited due to the toxic effects that these agents have on “normal” cells. The use of chemical mutagens such as MNU in MMR defective organisms is much more tolerable, yielding a 10 to 100 fold increase in genetic mutation over MMR deficiency alone (Bignani M, (2000) Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. *Mutat. Res.* 462:71-82). This strategy allows for the use of chemical mutagens to be used in MMR-defective Ab producing cells as a method for increasing additional mutations within immunoglobulin genes or chimeras that may yield functional Abs with altered biochemical properties such as enhanced binding affinity to antigen, *etc.*



**Example 5: establishment of genetic stability in hybridoma cells with new output trait.**

[0085] The initial steps of MMR are dependent on two protein complexes, called MutS $\alpha$  and MutL $\alpha$  (Nicolaidis *et al.* (1998) A Naturally Occurring hPMS2 Mutation Can Confer a Dominant Negative Mutator Phenotype. *Mol. Cell. Biol.* 18:1635-1641). Dominant negative MMR alleles are able to perturb the formation of these complexes with downstream biochemicals involved in the excision and polymerization of nucleotides comprising the "corrected" nucleotides. Examples from this application show the ability of a truncated MMR allele (PMS134) as well as a full length human PMS2 when expressed in a hybridoma cell line to block MMR resulting in a hypermutable cell line that gains genetic alterations throughout its entire genome per cell division. Once a cell line is produced that contains genetic alterations within genes encoding for an antibody, a single chain antibody, overexpression of immunoglobulin genes and/or enhanced secretion of antibody, it is desirable to restore the genomic integrity of the cell host. This can be achieved by the use of inducible vectors whereby dominant negative MMR genes are cloned into such vectors and introduced into Ab producing cells. The cells are cultured in the presence of inducer molecules and/or conditions. Inducible vectors include but are not limited to chemical regulated promoters such as the steroid inducible MMTV, tetracycline regulated promoters, temperature sensitive MMR gene alleles, and temperature sensitive promoters.

[0086] The results described above lead to several conclusions. First, expression of hPMS2 and PMS134 results in an increase in microsatellite instability in hybridoma cells. That this elevated microsatellite instability is due to MMR deficiency was proven by evaluation of extracts from stably transduced cells. The expression of PMS134 results in a polar defect in MMR, which was only observed using heteroduplexes designed to test repair from the 5' direction (no significant defect in repair from the 3' direction was observed in the same extracts) (Nicolaidis *et al.* (1998) A Naturally Occurring hPMS2 Mutation Can Confer a Dominant Negative Mutator Phenotype. *Mol. Cell. Biol.* 18:1635-1641). Interestingly, cells deficient in hMLH1 also have a polar defect in MMR, but in this case preferentially affecting repair from the 3' direction (Drummond, J.T., *et al.* (1996) Cisplatin and adriamycin resistance are associated with MutL $\alpha$  and mismatch repair deficiency in an ovarian tumor cell line. *J. Biol. Chem.* 271:9645-19648). It is known from previous studies in both prokaryotes and eukaryotes that the separate enzymatic components mediate repair from the two different directions. Our results, in combination with those of Drummond *et al.* (Shields, R.L., *et al.* (1995) Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release. *Int. Arch Allergy Immunol.* 107:412-413), strongly suggest a model in which 5' repair is primarily dependent on hPMS2 while 3'

repair is primarily dependent on hMLH1. The dimeric complex between PMS2 and MLH1 sets up this directionality. The combined results also demonstrate that a defect in directional MMR is sufficient to produce a MMR defective phenotype and suggests that any MMR gene allele is useful to produce genetically altered hybridoma cells, or a cell line that is producing Ig gene products. Moreover, the use of such MMR alleles will be useful for generating genetically altered Ig polypeptides with altered biochemical properties as well as cell hosts that produce enhanced amounts of antibody molecules.

[0087] Another method that is taught in this application is that any method used to block MMR can be performed to generate hypermutability in an antibody-producing cell that can lead to genetically altered antibodies with enhanced biochemical features such as but not limited to increased antigen binding, enhanced pharmacokinetic profiles, *etc.* These processes can also be used to generate antibody producer cells that have increased Ig expression as shown in Example 4, Figure 6 and/or increased antibody secretion as shown in Table 2.

[0088] In addition, we demonstrate the utility of blocking MMR in antibody producing cells to increase genetic alterations within Ig genes that may lead to altered biochemical features such as, but not limited to, increased antigen binding affinities (Figure 5A and SB). The blockade of MMR in such cells can be through the use of dominant negative MMR gene alleles from any species including bacteria, yeast, protozoa, insects, rodents, primates, mammalian cells, and man. Blockade of MMR can also be generated through the use of antisense RNA or deoxynucleotides directed to any of the genes involved in the MMR biochemical pathway. Blockade of MMR can be through the use of polypeptides that interfere with subunits of the MMR complex including but not limited to antibodies. Finally, the blockade of MMR may be through the use of chemicals such as but not limited to nonhydrolyzable ATP analogs, which have been shown to block MMR (Galio, L, *et al.* (1999) ATP hydrolysis-dependent formation of a dynamic ternary nucleoprotein complex with MutS and MutL. *Nucl. Acids Res.* 27:2325-2331).

#### **Example 6: Analysis of Genetic Sequence of mutant H36 cell lines producing high affinity antibodies**

[0089] The nucleic acid sequence of the light and heavy chains of the antibodies produced by the H36 mutant cell lines were examined for mutations within the immunoglobulin coding sequence that contribute to the increased affinity of the antibodies as compared to the parent clone. The results are shown in Table 3. The data show that proline substitutions in both the heavy and light chain variable domains contribute to increased affinity of the antibodies to antigen. A particular hot spot appears to be amino acid position 6 of SEQ ID NO:6 in which an

amino acid substitution occurred changing the parental alanine to proline for HB91-47, HB134DRMA13, and HB134DRMA55. These three clones also had mutations at positions 9 and 10. In position 9, the parental valine was changed to glycine or arginine, while at position 10 of SEQ ID NO:6, the parental arginine was changed to lysine in both cases.

Table 3

Clones	Chain	Sequence Change	Amino acid Change	Mean ELISA	Affinity
H36		WT	None	0.542	4.80E-08
HB-134a1	L	A>T	Thr>Ser	1.632	nd
HB91-34	H	C insertion	Frameshift	0	0
HB91-37	L	T>C	Leu>Pro	1.743	1.40E-09
HB91-38	H	T>A	Ser>Ser	1.641	nd
HB91-40	H	A>G	Ala>Thr	1.333	nd
HB91-47	H	Multiple	Ala>Pro, Val>Gly, Arg>Lys	1.979	3.12E-09
HB91-53	H	TT>AA	Phe>Lys	1.144	nd
HB91-62	H	A>G	Met>Gly	0.218	6.60E-07
HB91-71	H	T>G	Met>Gly	0.186	nd
HB134DRMA13	H	Multiple	Ala>Pro, Val>Gly, Arg>Lys, Thr>Ala	2.041	nd
HB134DRMA14	H	G>A, A>G	Arg>Lys, Thr>Ala	1.211	nd
HB134DRMA55	H	Multiple	Ala>Pro, Val>Arg, Arg>Lys, Thr>Glu, Ser>Thr	2.012	nd

[0090] The genetically altered antibodies show the following sequence differences and consensus sequence:

**Amino acid alignment of morphogenic HB91-47 heavy chain (SEQ ID NO:17), parental H36 heavy chain (SEQ ID NO:18), and consensus heavy chain sequence (SEQ ID NO:19)**

		1		35
Morphogenic	(1)	LQQSGPELGKPGTSVKISCKASGYTFTNYGMNWVK		
H36 parental	(1)	LQQSGAELVRPGTSVKISCKASGYTFTNYGMNWVK		
Consensus	(1)	LQQSG-EL--PGTSVKISCKASGYTFTNYGMNWVK		
			FR1	CDR1
		36		70
Morphogenic	(36)	QAPGKGLKWMGWINTYTGEPTYADDFKGRFAFSLE		
H36 parental	(36)	QAPGKGLKWMGWINTYTGEPTYADDFKGRFAFSLE		
Consensus	(36)	QAPGKGLKWMGWINTYTGEPTYADDFKGRFAFSLE		
			FR2	CDR2
				FR3

**Amino acid alignment of morphogenic HB91-37 light chain (SEQ ID NO:20), parental H36 light chain (SEQ ID NO:21), and consensus light chain sequence (SEQ ID NO:22)**

		1		35
Morphogenic	(1)	SASSSVSSSYFHWYQQKSGASPKPLIHRTSNLASG		
H36 parental	(1)	SASSSVSSSYFHWYQQKSGASLKPLIHRTSNLASG		
Consensus	(1)	SASSSVSSSYFHWYQQKSGAS-KPLIHRTSNLASG		
			CDR1	FR2
				CDR2
		36	45	
Morphogenic	(36)	VPARFSGSGS		
H36 parental	(36)	VPARFSGSGS		
Consensus	(36)	VPARFSGSGS		
			FR3	

**[0091]** The data shows that, for the light chain, a substitution in the second framework region (FR2) of the light chain at position 22 of SEQ ID NO:21 to a proline increased the binding affinity of the antibody.

**Example 7. An Efficient Screening System for Determining the Effector Function**

[0092] Increased antibody dependent cellular cytotoxicity (ADCC) elicited by antibody clone variants generated using the method of the invention maybe detected as follows: In one embodiment, human peripheral blood mononuclear cells (PBMCs), isolated from healthy donors are used as effector cells. Briefly, 400 ml of whole blood is diluted 1:1 (volume:volume) with phosphate buffer saline (PBS), laid onto Ficoll-Paque (Amersham) solution, and centrifuged at 2,000 RPM, 18°C, for 30 minutes. The interphase containing the mononuclear cells is recovered and transferred into a fresh tube and cells are washed with PBS. Red blood cells are then lysed using ACK lysing buffer (150 mM NH<sub>4</sub>Cl, 10 mM KHCO<sub>3</sub>, and 0.1 mM Na<sub>2</sub>EDTA) for 5 minutes at room temperature. PBMCs are washed again and their number and viability determined via trypan blue exclusion. Typically, greater than  $2 \times 10^8$  cells are recovered using this method, of which 60% endure the cryo-preservation and subsequent culturing (see below). PBMCs are then suspended in complete high glucose RPMI-1640 (Invitrogen), containing 10% fetal bovine serum (FBS) (Invitrogen), 2 mM L-glutamine (Invitrogen), 5% DMSO (Sigma), at a cell density of  $20 \times 10^6$ /ml. Cells are transferred into cryovials, 1 ml/vial, and stored at -80°C until use. Cells are quickly brought to 37°C, washed once using pre-warmed complete RPMI, re-suspended at a cell density of  $2.5 \times 10^6$ /ml in complete RPMI containing 10 ng/ml human recombinant interleukin 2 (hIL-2) (R&D Systems), and grown for 3 days at 37°C, 5% CO<sub>2</sub>. At the end of this incubation, PBMC viability is typically >85%, and the expected yield will allow the screening of greater than 600 antibody producing clones, assuming an effector:target cell ratio of 5:1. Before the assay, cells are washed once with PBS buffer, counted via trypan blue exclusion, suspended in CD-CHO serum-free medium (Invitrogen) and used for ADCC assay. The isolation of PBMCs from about ten donors will be required to screen 5,000 clones. In the past this number has been sufficient for the isolation of clones with desired characteristics. PBMCs from each donor will be used for separate runs of screening and never mixed with PBMCs of other donors.

[0093] In another embodiments, the use of human stable lines are used as an alternate source of effector cells. It has been reported that U937 and HL-60 cells (ATCC CRL-1593.2 and CCL-2, respectively) are capable of effector function (Sarmay G, Lund J, Rozsnyay Z, Gergely J, Jefferis R.). *Mol. Immunol.* 1992 May;29(5):633-9). This approach tests whether these cells elicit a cytolytic response against the target cells opsonized by the test antibody (e.g., an antibody against a tumor antigen applied to a tumor cell). Briefly, U937 or HL-60 cells will be cultured at 37°C, 5% CO<sub>2</sub>, in complete RPMI and stimulated with either 10 ng/ml recombinant human

interferon gamma (INF, R&D Systems) or with 100 ng/ml of phorbol 12-myristate 13-acetate (PMA, Sigma). After a 2-day incubation, cells are washed once with PBS buffer, counted via trypan blue exclusion, suspended in CD-CHO serum-free medium (Invitrogen) and used for ADCC assay.

#### **Example 8 Production of Cell Lines that Produce Improved Antibodies**

[0094] To generate phenotypically diversified cells for the selection of clones producing antibodies with increased ADCC activity, mAb-producing cells will be transfected with the vector p0124 (pEF1-hPMS2-134-IRES-TK) for the expression of the hPMS-134 gene, to inhibit mismatched DNA repair, using the Fugene reagent as described above. After selection using G41 8 (0.75 mg/ml), cells will be subcloned to isolate antibody producing clones concomitantly expressing hPMS-134 protein, as assessed by ELISA and western blotting, respectively. Cells will be allowed to expand for greater than 20 generations and then frozen and stored in liquid nitrogen until use.

#### **Example 9 Screening Cells for the Production of Antibodies with Enhanced Effector Function**

[0095] The mAb-producing cells expressing the hPMS-134 will be subcloned by limiting dilution and seeded in a flat-bottom 96-well plate. Seeding density will be determined empirically in order to obtain 40 single-cell colonies per plate to approximate monoclonality.

[0096] The clones will be allowed to grow for a number of days, which will be empirically determined, after which a sufficient amount of antibody, capable of mediating ADCC activity, is produced. Because the parental antibody can elicit ADCC activity at concentrations as low as 100 ng/ml, we predict that incubating the single cell-derived clones for 10-15 days should result in the production of sufficient antibodies to support effector function. At the end of this incubation period, 50 ul of conditioned medium from each clone/well will be used to assess concentration of antibodies by ELISA, while another 50 ul of conditioned medium from the same well/clone will be utilized in the ADCC assay. Briefly, for example, an anti-ovarian cancer mAb are used in conjunction with the target cells, SKOV3 (passage 1 to 20, obtained from ATCC), which are seeded the day before the assay in a flat-bottom 96-well microplate at a density of 30,000 cell/well in complete growth medium (RPMI-1640 containing 10% FBS, 2 mM L-glutamine). The following day, the complete medium is replaced with 100 ul of CHO-CD serum-free medium and 50 ul of antibody-containing conditioned medium will be added to target cells and incubated for 20 minutes at 37°C. Subsequently, 100 ul of serum-free

medium containing  $2 \times 10^5$  of effector cells are added to each well and cells are incubated for 5-6 hours at 37°C, 5% CO<sub>2</sub>. Plates are then briefly centrifuged and 100 ul of supernatant is collected from each well and transferred into ELISA plates (Nunc). One hundred ul of LDH substrate (Roche) is added to supernatants and incubated for 10 minutes at ambient temperature. LDH activity will be proportional to the extent of the LDH enzyme released from lysed target cells. Optical density at 490 nm (OD<sub>490</sub>) is obtained spectrophotometrically and percent of cytotoxicity is determined with the formula:  $(\text{sample OD}_{490} - \text{spontaneous OD}_{490}) / (\text{max OD}_{490} - \text{spontaneous OD}_{490}) \times 100\%$ , where 'spontaneous' = target cells lysis in absence of effector cells or antibody, and 'max' = target cells lysis in the presence of 2% Triton. Cytotoxicity elicited by 100 ng/ml of a reference antibody (protein A purified, parental antibody) will be used as positive control. Non-specific cytotoxicity will be monitored using 100 mg/ml of normal human IgG1. The ratio obtained by dividing the % cytotoxicity by the concentration of the antibody for each well/clone (*i.e.*, ratio = 50(%) / 100(ng/ml) = 0.5) will be set as the criterion for selecting lead clones with potentially enhanced effector function. Lead clones will be expanded to 50 ml cultures and antibody will be purified from their conditioned media by protein-A affinity column as described. ADCC activities of the antibodies produced by the lead clones will be compared to the parental antibody using concentrations ranging from 10-1000 ng/ml.

#### **Example 10 Correlating Effector Function and Receptor Binding Activity**

[0097] One of the major modes of action of unconjugated therapeutic monoclonal antibodies directed against tumor antigens is through recruitment of immune effector populations to the tumor cells (Clynes R, Takechi Y, Moroi Y, Houghton A, Ravetch JV. *Proc. Natl. Acad. Sci. U.S.A.* 1998 Jan 20;95(2):652-6; Clynes RA, Towers TL, Presta LG, Ravetch JV. *Nat. Med.* 2000 Apr;6(4):443-6). It is presumed that the efficiency with which a given antibody can recruit immune effector cells to a tumor cell is influenced by the affinity of the antibody for its cognate antigen on the tumor cell surface, such that a high affinity antibody will display more efficient recruitment of immune effectors to the tumor cell than a lower affinity counterpart recognizing the same antigen. Limited reports have attempted to demonstrate this relation *in vitro* (Alsmadi, O. and Tilley, SA. *J. Virol.* 1998 Jan;72(1):286-293; McCall, AM., Shahied, L., Amoroso, AR., Horak, EM., Simmons, RH., Nielson, U., Adams, GP., Schier, R., Marks, JD., Weiner, LM. *J. Immunol.* 2001 May 15;166(10):6112-7, as well as *in vivo* (Velders, MP, van Rhijn, CM., Oskam, GJ., Warnaar, SO. and Litvinov, SV. *J. Cancer* 1998;78(4):476-483). In order to determine if such a correlation exists, *in vitro* ADCC activity of enhanced mAbs, and the affinity

of these antibodies may be compared for their relevant antigen by surface plasmon resonance spectroscopy.

[0098] Surface plasmon resonance spectroscopy relies on the short range (~150nm) interaction of the electrical field (evanescent wave) generated by photons under conditions of total internal reflection (TIR) with electrons (surface plasmons) in a conductive film at the boundary between two media of differing refractive indices, whereby one of the media is a thin gold layer (conductive film) coated with an alkane linker coupled to CM-dextran. The CM-dextran surface, which forms an extended hydrogel in solution, projecting roughly 100-150 nm into the flowcell, may be derivatized further with a ligand of choice by covalent immobilization to the carboxyl groups present on the CM-dextran layer. The angle necessary to allow the evanescent wave to interact with the gold layer will depend on the angle necessary to observe TIR, which in turn depends on the thickness or mass at the surface of the chip. The instrument thus allows for observation of the change in mass at the surface of the chip over time, as would be observed when an analyte which interacts with the immobilized ligand is injected into the flowcell. If injection of analyte is followed by injection of buffer, one can follow both the association (during injection of the analyte) and dissociation phases (during buffer injection) of the binding. Kinetic on-rates ( $k_a$ ) and off-rates ( $k_d$ ), as well as steady-state equilibrium constants ( $K_a$  and  $K_d$ ) can thus be extrapolated.

[0099] The soluble, secreted form of the antigen will be purified from the serum-free culture supernatant of target cells by chromatography through Phenyl Sepharose (high sub), followed by ion exchange on S Sepharose Fast Flow. Briefly, culture supernatant containing secreted antigen will be loaded onto the Phenyl Sepharose (high sub) column in the absence of additional salts. Unbound proteins will be removed by extensive washing in HIC A (20 mM K phosphate pH 7.2), followed by elution of bound antigen using a linear gradient of 0-20 mM CHAPS in HIC buffer. Peak MORAb-03-containing fractions will be pooled, acidified (pH 5.5) with 1 M citrate, then applied to a S Sepharose cation exchange column. After washing with IEX buffer (20 mM K phosphate, pH 5.5), bound antigen will be eluted using a linear gradient of 0-1 M NaCl in IEX buffer. Peak fractions will be pooled, concentrated using a Centricon centrifugal concentration device (Millipore), and dialyzed against PBS. Based on the purity of the antigen preparation, an additional affinity chromatography step on covalently coupled folate Sepharose resin may be necessary (Sadasivan, E., da Costa, M., Rothenberg, SP. and Brink, L. *Biochim. Biophys. Acta* 1987;(925):36-47).

[0100] The mAb to be assayed will be purified in one step by affinity chromatography on recombinant protein A Sepharose resin (RPA-Sepharose, Amersham Biosciences).




Immunoglobulin (Ig) containing tissue culture supernatants will be loaded onto RPAsepharose columns by gravity, at a Ig/ml resin value of 10 mg/mL of resin. Unbound proteins will be removed by extensive washing with PBS, followed by elution using 0.1 M glycine-HCl pH 2.6. Fractions will be neutralized with 1 M Tris. Peak fractions will be pooled, and dialyzed against 1000 volumes of PBS. Ig concentration will be determined by BCA protein assay (Pierce Chemical Co.) and Ig-specific ELISA.

[0101] Purified antigen will be diluted into coupling buffer (10 mM NaOAc pH 5.0), and immobilized onto the flowcell of a CM5 sensor chip (Biacore) by amine coupling, using a mixture of N-hydroxysuccinimide (NHS) and 1-ethyl-3-[dimethylaminopropyl] carbodiimide hydrochloride (EDC) to activate carboxyl groups in the CM-Dextran hydrogel attached to the surface of the CM5 sensor chip. Activated, underivatized carboxyl groups will be quenched with 1 M ethanolamine. A reference flowcell, consisting of the quenched CMDextran surface, activated in the absence of antigen, will be used to normalize all measurements. Crude, mAb-containing culture supernatants, or purified mAb preparations will be injected at flow rates of 30 ul/min for kinetic assays, and 5 ul/min for steady-state affinity ranking experiments, using HBS-EP (20 mM HEPES-OH, 150 mM NaCl, 3 mM EDTA, 0.005% Surfactant P-20, pH 7.4) as running buffer. Purified mAb preparations will be dialyzed against HBS-EP, using 10K MWCO Slide-A-Lyzer dialysis cassettes (Pierce) prior to their use in Biacore analysis. For samples containing tissue culture supernatant, BSA and soluble CM-Dextran will be added to final concentrations of 1 % and 1 mg/ml, respectively. Regeneration of the surface will be accomplished by 30 second injection of 50 mM NaOH, at a flow rate of 100 ul/min. Data analysis will be performed using Bia Evaluation software (Biacore). Kinetic data will be fitted to a simple 1:1 (Langmuir) binding model. For ranking experiments, rank will be determined by  $K_D$  values obtained from plots of  $R_{eq}$  versus C at different concentrations of sample.

## What is Claimed:

1. A method of producing an antibody with enhanced effector function comprising introducing into an antibody-producing cell a dominant negative allele of a mismatch repair gene, whereby said antibody-producing cell becomes hypermutable; screening said hypermutable cells for cells that produce antibodies with increased effector function, thereby producing an antibody with enhanced effector function.
2. The method of claim 1 wherein said dominant negative allele is a *PMS2* allele.
3. The method of claim 2 wherein said *PMS2* allele comprises a truncation mutation at codon 134.
4. The method of claim 3 wherein said truncation mutation is a thymidine at nucleotide 424 of wild-type *PMS2*.
5. The method of claim 3 wherein said *PMS2* allele encodes the first 133 amino acids of wild-type *PMS2*.
6. The method of claim 2 wherein the *PMS2* allele is human *PMS2*.
7. The method of claim 1 wherein said effector function is antibody-dependent cytotoxicity (ADCC) activity.
8. The method of claim 1 further comprising restoring genetic stability to said antibody-producing cell.
9. The method of claim 1 further comprising exposing said antibody-producing cell to a chemical mutagen.
10. The method of claim 1 wherein said antibody comprises an amino acid substitution with proline or hydroxyproline.
11. The method of claim 1 wherein said antibody comprises an amino acid substitution in a heavy chain variable region.

12. The method of claim 1 wherein said antibody comprises an amino acid substitution in a light chain variable region.
13. The method of claim 1 wherein said antibody comprises an amino acid substitution in a first framework region of a heavy chain.
14. The method of claim 13 wherein said substitution occurs at position 6 of a first framework region comprising the amino acid sequence of SEQ ID NO:18.
15. The method of claim 1 wherein said antibody comprises an amino acid substitution in a second framework region of a light chain.
16. The method of claim 14 wherein said amino acid substitution comprises proline or hydroxyproline.
17. The method of claim 15 wherein said substitution occurs at position 22 of a second framework region comprising the amino acid sequence of SEQ ID NO:21.
18. The method of claim 1 wherein said antibody comprises an amino acid substitution in a first framework region of a heavy chain and an amino acid substitution in a second framework region of a light chain.
19. The method of claim 17 wherein said amino acid substitution comprises proline or hydroxyproline.
20. An antibody having enhanced effector function produced according to the method of claim 1.



**Fig. 1**




Fig. 2

3/8

Fig. 3






Fig. 4



5/8

HB134



Consensus sequence

TAAAT AAGTT GCAT

H36




Fig. 5A



6/8




Fig. 5B

7/8




Fig. 6

8/8




Fig. 7

MOR0312.ST25.txt  
SEQUENCE LISTING

<110> Morphotek Inc.  
Grasso, Luigi  
Nicolaidis, Nicholas C.  
Sands, Howard

<120> ANTIBODIES AND METHODS FOR GENERATING GENETICALLY ALTERED  
ANTIBODIES WITH ENHANCED EFFECTOR FUNCTION

<130> MOR-0312

<150> US 60/491,310  
<151> 2003-07-29

<160> 24

<170> PatentIn version 3.2

<210> 1  
<211> 24  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Primer

<400> 1  
ggattttcag gtgcagattt tcag 24

<210> 2  
<211> 21  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Primer

<400> 2  
actggatggt gggaagatgg a 21

<210> 3  
<211> 19  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Primer

<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> n = g or t

<220>  
<221> misc\_feature  
<222> (5)..(5)  
<223> n is a, c, g, or t

<220>  
<221> misc\_feature  
<222> (6)..(6)  
<223> n = a or c

<220>  
<221> misc\_feature  
<222> (11)..(11)

MOR0312.ST25.txt

&lt;223&gt; n is a, c, g, or t

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (15)..(15)

&lt;223&gt; n = c or g

&lt;400&gt; 3

angtnnagct ncagnagtc

19

&lt;210&gt; 4

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Primer

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (2)..(2)

&lt;223&gt; n is a, c, g, or t

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (8)..(8)

&lt;223&gt; n = a or g

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (17)..(17)

&lt;223&gt; n = g or a

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (18)..(18)

&lt;223&gt; n = a or t

&lt;400&gt; 4

tnccttgnc cagtannc

19

&lt;210&gt; 5

&lt;211&gt; 859

&lt;212&gt; PRT

&lt;213&gt; Mus musculus

&lt;400&gt; 5

Met	Glu	Gln	Thr	Glu	Gly	Val	Ser	Thr	Glu	Cys	Ala	Lys	Ala	Ile	Lys
1				5					10					15	

Pro	Ile	Asp	Gly	Lys	Ser	Val	His	Gln	Ile	Cys	Ser	Gly	Gln	Val	Ile
		20					25						30		

Leu	Ser	Leu	Ser	Thr	Ala	Val	Lys	Glu	Leu	Ile	Glu	Asn	Ser	Val	Asp
		35					40					45			

Ala	Gly	Ala	Thr	Thr	Ile	Asp	Leu	Arg	Leu	Lys	Asp	Tyr	Gly	Val	Asp
	50					55					60				

Leu	Ile	Glu	Val	Ser	Asp	Asn	Gly	Cys	Gly	Val	Glu	Glu	Glu	Asn	Phe
65					70					75					80

Glu	Gly	Leu	Ala	Leu	Lys	His	His	Thr	Ser	Lys	Ile	Gln	Glu	Phe	Ala		
				85					90							95	
Asp	Leu	Thr	Gln	Val	Glu	Thr	Phe	Gly	Phe	Arg	Gly	Glu	Ala	Leu	Ser		
				100					105							110	
Ser	Leu	Cys	Ala	Leu	Ser	Asp	Val	Thr	Ile	Ser	Thr	Cys	His	Gly	Ser		
				115					120							125	
Ala	Ser	Val	Gly	Thr	Arg	Leu	Val	Phe	Asp	His	Asn	Gly	Lys	Ile	Thr		
				130					135							140	
Gln	Lys	Thr	Pro	Tyr	Pro	Arg	Pro	Lys	Gly	Thr	Thr	Val	Ser	Val	Gln		
				145					150							155	160
His	Leu	Phe	Tyr	Thr	Leu	Pro	Val	Arg	Tyr	Lys	Glu	Phe	Gln	Arg	Asn		
				165					170							175	
Ile	Lys	Lys	Glu	Tyr	Ser	Lys	Met	Val	Gln	Val	Leu	Gln	Ala	Tyr	Cys		
				180					185							190	
Ile	Ile	Ser	Ala	Gly	Val	Arg	Val	Ser	Cys	Thr	Asn	Gln	Leu	Gly	Gln		
				195					200							205	
Gly	Lys	Arg	His	Ala	Val	Val	Cys	Thr	Ser	Gly	Thr	Ser	Gly	Met	Lys		
				210					215							220	
Glu	Asn	Ile	Gly	Ser	Val	Phe	Gly	Gln	Lys	Gln	Leu	Gln	Ser	Leu	Ile		
				225					230							235	240
Pro	Phe	Val	Gln	Leu	Pro	Pro	Ser	Asp	Ala	Val	Cys	Glu	Glu	Tyr	Gly		
				245					250							255	
Leu	Ser	Thr	Ser	Gly	Arg	His	Lys	Thr	Phe	Ser	Thr	Phe	Arg	Ala	Ser		
				260					265							270	
Phe	His	Ser	Ala	Arg	Thr	Ala	Pro	Gly	Gly	Val	Gln	Gln	Thr	Gly	Ser		
				275					280							285	
Phe	Ser	Ser	Ser	Ile	Arg	Gly	Pro	Val	Thr	Gln	Gln	Arg	Ser	Leu	Ser		
				290					295							300	
Leu	Ser	Met	Arg	Phe	Tyr	His	Met	Tyr	Asn	Arg	His	Gln	Tyr	Pro	Phe		
				305					310							315	320
Val	Val	Leu	Asn	Val	Ser	Val	Asp	Ser	Glu	Cys	Val	Asp	Ile	Asn	Val		
				325					330							335	
Thr	Pro	Asp	Lys	Arg	Gln	Ile	Leu	Leu	Gln	Glu	Glu	Lys	Leu	Leu	Leu		
				340					345							350	
Ala	Val	Leu	Lys	Thr	Ser	Leu	Ile	Gly	Met	Phe	Asp	Ser	Asp	Ala	Asn		

	MOR0312.ST25.txt														
355				360				365							
Lys 370	Leu	Asn	Val	Asn	Gln	Gln	Pro	Leu	Leu	Asp	Val	Glu	Gly	Asn	Leu
						375					380				
Val 385	Lys	Leu	His	Thr	Ala	Glu	Leu	Glu	Lys	Pro	Val	Pro	Gly	Lys	Gln
					390					395					400
Asp	Asn	Ser	Pro	Ser	Leu	Lys	Ser	Thr	Ala	Asp	Glu	Lys	Arg	Val	Ala
				405					410					415	
Ser	Ile	Ser	Arg	Leu	Arg	Glu	Ala	Phe	Ser	Leu	His	Pro	Thr	Lys	Glu
			420					425					430		
Ile	Lys	Ser	Arg	Gly	Pro	Glu	Thr	Ala	Glu	Leu	Thr	Arg	Ser	Phe	Pro
			435				440					445			
Ser	Glu	Lys	Arg	Gly	Val	Leu	Ser	Ser	Tyr	Pro	Ser	Asp	Val	Ile	Ser
	450					455					460				
Tyr	Arg	Gly	Leu	Arg	Gly	Ser	Gln	Asp	Lys	Leu	Val	Ser	Pro	Thr	Asp
465					470					475					480
Ser	Pro	Gly	Asp	Cys	Met	Asp	Arg	Glu	Lys	Ile	Glu	Lys	Asp	Ser	Gly
				485					490					495	
Leu	Ser	Ser	Thr	Ser	Ala	Gly	Ser	Glu	Glu	Glu	Phe	Ser	Thr	Pro	Glu
			500					505					510		
Val	Ala	Ser	Ser	Phe	Ser	Ser	Asp	Tyr	Asn	Val	Ser	Ser	Leu	Glu	Asp
		515					520					525			
Arg	Pro	Ser	Gln	Glu	Thr	Ile	Asn	Cys	Gly	Asp	Leu	Asp	Cys	Arg	Pro
	530					535					540				
Pro	Gly	Thr	Gly	Gln	Ser	Leu	Lys	Pro	Glu	Asp	His	Gly	Tyr	Gln	Cys
545					550					555					560
Lys	Ala	Leu	Pro	Leu	Ala	Arg	Leu	Ser	Pro	Thr	Asn	Ala	Lys	Arg	Phe
				565					570					575	
Lys	Thr	Glu	Glu	Arg	Pro	Ser	Asn	Val	Asn	Ile	Ser	Gln	Arg	Leu	Pro
			580					585					590		
Gly	Pro	Gln	Ser	Thr	Ser	Ala	Ala	Glu	Val	Asp	Val	Ala	Ile	Lys	Met
		595					600					605			
Asn	Lys	Arg	Ile	Val	Leu	Leu	Glu	Phe	Ser	Leu	Ser	Ser	Leu	Ala	Lys
	610					615					620				
Arg	Met	Lys	Gln	Leu	Gln	His	Leu	Lys	Ala	Gln	Asn	Lys	His	Glu	Leu
625					630					635					640

MOR0312.ST25.txt

Ser Tyr Arg Lys Phe Arg Ala Lys Ile Cys Pro Gly Glu Asn Gln Ala  
645 650 655

Ala Glu Asp Glu Leu Arg Lys Glu Ile Ser Lys Ser Met Phe Ala Glu  
660 665 670

Met Glu Ile Leu Gly Gln Phe Asn Leu Gly Phe Ile Val Thr Lys Leu  
675 680 685

Lys Glu Asp Leu Phe Leu Val Asp Gln His Ala Ala Asp Glu Lys Tyr  
690 695 700

Asn Phe Glu Met Leu Gln Gln His Thr Val Leu Gln Ala Gln Arg Leu  
705 710 715 720

Ile Thr Pro Gln Thr Leu Asn Leu Thr Ala Val Asn Glu Ala Val Leu  
725 730 735

Ile Glu Asn Leu Glu Ile Phe Arg Lys Asn Gly Phe Asp Phe Val Ile  
740 745 750

Asp Glu Asp Ala Pro Val Thr Glu Arg Ala Lys Leu Ile Ser Leu Pro  
755 760 765

Thr Ser Lys Asn Trp Thr Phe Gly Pro Gln Asp Ile Asp Glu Leu Ile  
770 775 780

Phe Met Leu Ser Asp Ser Pro Gly Val Met Cys Arg Pro Ser Arg Val  
785 790 795 800

Arg Gln Met Phe Ala Ser Arg Ala Cys Arg Lys Ser Val Met Ile Gly  
805 810 815

Thr Ala Leu Asn Ala Ser Glu Met Lys Lys Leu Ile Thr His Met Gly  
820 825 830

Glu Met Asp His Pro Trp Asn Cys Pro His Gly Arg Pro Thr Met Arg  
835 840 845

His Val Ala Asn Leu Asp Val Ile Ser Gln Asn  
850 855

<210> 6  
<211> 3056  
<212> DNA  
<213> Mus musculus

<400> 6  
gaattccggt gaaggtcctg aagaatttcc agattcctga gtatcattgg aggagacaga 60  
taacctgtcg tcaggtaacg atgggtgtata tgcaacagaa atgggtgttc ctggagacgc 120  
gtcttttccc gagagcggca ccgcaactct cccgcggtga ctgtgactgg aggagtcctg 180  
catccatgga gcaaaccgaa ggcgtgagta cagaatgtgc taaggccatc aagcctattg 240



MOR0312.ST25.txt

atgggaagtc agtccatcaa atttgttctg ggcaggatgat actcagttta agcaccgctg	300
tgaaggagtt gatagaaaat agtgtagatg ctggtgctac tactattgat ctaaggctta	360
aagactatgg ggtggacctc attgaagttt cagacaatgg atgtggggta gaagaagaaa	420
actttgaagg tctagctctg aaacatcaca catctaagat tcaagagttt gccgacctca	480
cgcagggtga aactttcggc tttcgggggg aagctctgag ctctctgtgt gactaagtg	540
atgtcactat atctacctgc cacgggtctg caagcgttgg gactcgactg gtgtttgacc	600
ataatgggaa aatcaccag aaaactccct acccccgacc taaaggaacc acagtcagt	660
tgcagcactt attttataca ctaccctgct gttacaaaga gtttcagagg aacattaaaa	720
aggagtattc caaaatggtg caggctctac aggcgtactg tatcatctca gcaggcgtcc	780
gtgtaagctg cactaatcag ctccgacagg ggaagcggca cgtgtgtgtg tgcacaagcg	840
gcacgtctgg catgaaggaa aatatcgggt ctgtgtttgg ccagaagcag ttgcaaagcc	900
tcattccttt tgttcagctg cccctagtg acgctgtgtg tgaagagtac ggctgagca	960
cttcaggacg ccacaaaacc tttctacgt ttcgggcttc atttcacagt gcacgcacgg	1020
cgcggggagg agtgcaacag acaggcagtt tttcttcac aatcagaggc cctgtgaccc	1080
agcaaaggtc tctaagcttg tcaatgaggt tttatcacat gtataaccgg catcagtacc	1140
catttgcgt ccttaacgtt tccgttgact cagaatgtgt ggatattaat gtaactccag	1200
ataaaaggca aattctacta caagaagaga agctattgtt gccggtttta aagacctcct	1260
tgataggaat gtttgacagt gatgcaaaca agcttaatgt caaccagcag ccactgctag	1320
atgttgaggg taacttagta aagctgcata ctgcagaact agaaaagcct gtgccaggaa	1380
agcaagataa ctctccttca ctgaagagca cagcagacga gaaaagggtg gcatccatct	1440
ccaggctgag agaggccttt tctcttcac ctactaaaga gatcaagtct aggggtccag	1500
agactgctga actgacacgg agttttccaa gtgagaaaag gggcgtgtta tctcttctc	1560
cttcagacgt catctcttac agaggcctcc gtggctcgca ggacaaattg gtgagtccca	1620
cggacagccc tgggtgactgt atggacagag agaaaataga aaaagactca gggctcagca	1680
gcacctcagc tggctctgag gaagagttca gcacccaga agtggccagt agcttttagca	1740
gtgactataa cgtgagctcc ctagaagaca gacctctca ggaaaccata aactgtggtg	1800
acctggactg ccgtcctcca ggtacaggac agtccttgaa gccagaagac catggatctc	1860
aatgcaaagc tctacctcta gctcgtctgt caccacaaa tgccaagcgc ttcaagacag	1920
aggaaagacc ctcaaatgtc aacatttctc aaagattgcc tggctctcag agcacctcag	1980
cagctgaggt cgatgtagcc ataaaaatga ataagagaat cgtgctcctc gagttctctc	2040
tgagttctct agctaagcga atgaagcagt tacagcacct aaaggcgcag aacaaacatg	2100
aactgagtta cagaaaattt agggccaaga tttgccctgg agaaaaccaa gcagcagaag	2160
atgaactcag aaaagagatt agtaaatcga tgtttgcaga gatggagatc ttgggtcagt	2220
ttaacctggg atttatagta accaaactga aagaggacct cttcctgggtg gaccagcatg	2280
ctgcggatga gaagtacaac tttgagatgc tgcagcagca cacgggtgctc caggcgcaga	2340

## MOR0312.ST25.txt

```

ggctcatcac accccagact ctgaacttaa ctgctgtcaa tgaagctgta ctgatagaaa 2400
atctggaaat attcagaaag aatggctttg actttgtcat tgatgaggat gctccagtca 2460
ctgaaagggc taaattgatt tccttaccaa ctagtaaaaa ctggaccttt ggacccaag 2520
atatagatga actgatcttt atgttaagtg acagccctgg ggtcatgtgc cggccctcac 2580
gagtcagaca gatgtttgct tccagagcct gtcggaagtc agtgatgatt ggaacggcgc 2640
tcaatgcgag cgagatgaag aagctcatca cccacatggg tgagatggac caccctgga 2700
actgccccca cggcaggcca accatgaggc acgttgccaa tctggatgac atctctcaga 2760
actgacacac cccttgtagc atagagttaa ttacagattg ttcggtttgc aaagagaagg 2820
ttttaagtaa tctgattatc gttgtacaaa aattagcatg ctgctttaat gtactggatc 2880
catttaaaag cagtgttaag gcaggcatga tggagtgttc ctctagctca gctacttggg 2940
tgatccggtg ggagctcatg tgagcccagg actttgagac cactccgagc cacattcatg 3000
agactcaatt caaggacaaa aaaaaaaga tatttttgaa gccttttaaa aaaaaa 3056

```

```

<210> 7
<211> 862
<212> PRT
<213> Homo sapiens

```

```

<400> 7

```

```

Met Glu Arg Ala Glu Ser Ser Ser Thr Glu Pro Ala Lys Ala Ile Lys
1             5             10             15

```

```

Pro Ile Asp Arg Lys Ser Val His Gln Ile Cys Ser Gly Gln Val Val
20             25             30

```

```

Leu Ser Leu Ser Thr Ala Val Lys Glu Leu Val Glu Asn Ser Leu Asp
35             40             45

```

```

Ala Gly Ala Thr Asn Ile Asp Leu Lys Leu Lys Asp Tyr Gly Val Asp
50             55             60

```

```

Leu Ile Glu Val Ser Asp Asn Gly Cys Gly Val Glu Glu Glu Asn Phe
65             70             75             80

```

```

Glu Gly Leu Thr Leu Lys His His Thr Ser Lys Ile Gln Glu Phe Ala
85             90             95

```

```

Asp Leu Thr Gln Val Glu Thr Phe Gly Phe Arg Gly Glu Ala Leu Ser
100            105            110

```

```

Ser Leu Cys Ala Leu Ser Asp Val Thr Ile Ser Thr Cys His Ala Ser
115            120            125

```

```

Ala Lys Val Gly Thr Arg Leu Met Phe Asp His Asn Gly Lys Ile Ile
130            135            140

```

```

Gln Lys Thr Pro Tyr Pro Arg Pro Arg Gly Thr Thr Val Ser Val Gln

```

MOR0312.ST25.txt

145	150	155	160
Gln Leu Phe Ser Thr Leu Pro Val Arg His Lys Glu Phe Gln Arg Asn	165	170	175
Ile Lys Lys Glu Tyr Ala Lys Met Val Gln Val Leu His Ala Tyr Cys	180	185	190
Ile Ile Ser Ala Gly Ile Arg Val Ser Cys Thr Asn Gln Leu Gly Gln	195	200	205
Gly Lys Arg Gln Pro Val Val Cys Thr Gly Gly Ser Pro Ser Ile Lys	210	215	220
Glu Asn Ile Gly Ser Val Phe Gly Gln Lys Gln Leu Gln Ser Leu Ile	225	230	235
Pro Phe Val Gln Leu Pro Pro Ser Asp Ser Val Cys Glu Glu Tyr Gly	245	250	255
Leu Ser Cys Ser Asp Ala Leu His Asn Leu Phe Tyr Ile Ser Gly Phe	260	265	270
Ile Ser Gln Cys Thr His Gly Val Gly Arg Ser Ser Thr Asp Arg Gln	275	280	285
Phe Phe Phe Ile Asn Arg Arg Pro Cys Asp Pro Ala Lys Val Cys Arg	290	295	300
Leu Val Asn Glu Val Tyr His Met Tyr Asn Arg His Gln Tyr Pro Phe	305	310	315
Val Val Leu Asn Ile Ser Val Asp Ser Glu Cys Val Asp Ile Asn Val	325	330	335
Thr Pro Asp Lys Arg Gln Ile Leu Leu Gln Glu Glu Lys Leu Leu Leu	340	345	350
Ala Val Leu Lys Thr Ser Leu Ile Gly Met Phe Asp Ser Asp Val Asn	355	360	365
Lys Leu Asn Val Ser Gln Gln Pro Leu Leu Asp Val Glu Gly Asn Leu	370	375	380
Ile Lys Met His Ala Ala Asp Leu Glu Lys Pro Met Val Glu Lys Gln	385	390	395
Asp Gln Ser Pro Ser Leu Arg Thr Gly Glu Glu Lys Lys Asp Val Ser	405	410	415
Ile Ser Arg Leu Arg Glu Ala Phe Ser Leu Arg His Thr Thr Glu Asn	420	425	430

MOR0312.ST25.txt

Lys Pro His Ser Pro Lys Thr Pro Glu Pro Arg Arg Ser Pro Leu Gly  
 435 440 445  
 Gln Lys Arg Gly Met Leu Ser Ser Ser Thr Ser Gly Ala Ile Ser Asp  
 450 455 460  
 Lys Gly Val Leu Arg Pro Gln Lys Glu Ala Val Ser Ser Ser His Gly  
 465 470 475 480  
 Pro Ser Asp Pro Thr Asp Arg Ala Glu Val Glu Lys Asp Ser Gly His  
 485 490 495  
 Gly Ser Thr Ser Val Asp Ser Glu Gly Phe Ser Ile Pro Asp Thr Gly  
 500 505 510  
 Ser His Cys Ser Ser Glu Tyr Ala Ala Ser Ser Pro Gly Asp Arg Gly  
 515 520 525  
 Ser Gln Glu His Val Asp Ser Gln Glu Lys Ala Pro Glu Thr Asp Asp  
 530 535 540  
 Ser Phe Ser Asp Val Asp Cys His Ser Asn Gln Glu Asp Thr Gly Cys  
 545 550 555 560  
 Lys Phe Arg Val Leu Pro Gln Pro Thr Asn Leu Ala Thr Pro Asn Thr  
 565 570 575  
 Lys Arg Phe Lys Lys Glu Glu Ile Leu Ser Ser Ser Asp Ile Cys Gln  
 580 585 590  
 Lys Leu Val Asn Thr Gln Asp Met Ser Ala Ser Gln Val Asp Val Ala  
 595 600 605  
 Val Lys Ile Asn Lys Lys Val Val Pro Leu Asp Phe Ser Met Ser Ser  
 610 615 620  
 Leu Ala Lys Arg Ile Lys Gln Leu His His Glu Ala Gln Gln Ser Glu  
 625 630 635 640  
 Gly Glu Gln Asn Tyr Arg Lys Phe Arg Ala Lys Ile Cys Pro Gly Glu  
 645 650 655  
 Asn Gln Ala Ala Glu Asp Glu Leu Arg Lys Glu Ile Ser Lys Thr Met  
 660 665 670  
 Phe Ala Glu Met Glu Ile Ile Gly Gln Phe Asn Leu Gly Phe Ile Ile  
 675 680 685  
 Thr Lys Leu Asn Glu Asp Ile Phe Ile Val Asp Gln His Ala Thr Asp  
 690 695 700  
 Glu Lys Tyr Asn Phe Glu Met Leu Gln Gln His Thr Val Leu Gln Gly

MOR0312.ST25.txt

705	710	715	720
Gln Arg Leu Ile Ala Pro Gln Thr Leu Asn Leu Thr Ala Val Asn Glu	725	730	735
Ala Val Leu Ile Glu Asn Leu Glu Ile Phe Arg Lys Asn Gly Phe Asp	740	745	750
Phe Val Ile Asp Glu Asn Ala Pro Val Thr Glu Arg Ala Lys Leu Ile	755	760	765
Ser Leu Pro Thr Ser Lys Asn Trp Thr Phe Gly Pro Gln Asp Val Asp	770	775	780
Glu Leu Ile Phe Met Leu Ser Asp Ser Pro Gly Val Met Cys Arg Pro	785	790	795
Ser Arg Val Lys Gln Met Phe Ala Ser Arg Ala Cys Arg Lys Ser Val	805	810	815
Met Ile Gly Thr Ala Leu Asn Thr Ser Glu Met Lys Lys Leu Ile Thr	820	825	830
His Met Gly Glu Met Asp His Pro Trp Asn Cys Pro His Gly Arg Pro	835	840	845
Thr Met Arg His Ile Ala Asn Leu Gly Val Ile Ser Gln Asn	850	855	860

<210> 8  
 <211> 2771  
 <212> DNA  
 <213> Homo sapiens

<400> 8  
 cgaggcggat cggtgtgtgc atccatggag cgagctgaga gctcgagtac agaactgct 60  
 aaggccatca aacctattga tcggaagtca gtccatcaga ttgtctctgg gcaggtggtg 120  
 ctgagtctaa gcaactgcgt aaaggagtta gtagaaaaca gtctggatgc tgggtccact 180  
 aatattgata taaagcttaa ggactatgga gtggatctta ttgaagtttc agacaatgga 240  
 tgtggggtag aagaagaaaa ctctgaaggc ttaactctga aacatcacac atctaagatt 300  
 caagagtttg ccgacctaac tcagggtgaa acttttggct ttcgggggga agctctgagc 360  
 tcactttgtg cactgagcga tgtcaccatt tctacctgcc acgcatcggc gaagggttga 420  
 actcgactga tgtttgatca caatgggaaa attatccaga aaaccccta ccccgcccc 480  
 agagggacca cagtcagcgt gcagcagtta tttccacac tacctgtgcg ccataaggaa 540  
 tttcaaagga atattaagaa ggagtatgcc aaaatggtcc aggtcttaca tgcatactgt 600  
 atcatttcag caggcatccg tgtaagttgc accaatcagc ttggacaagg aaaacgacag 660  
 cctgtggtat gcacaggtgg aagccccagc ataaaggaaa atatcggctc tgtgtttggg 720  
 cagaagcagt tgcaaacct cattcctttt gttcagctgc cccctagtga ctccgtgtgt 780

## MOR0312.ST25.txt

```

gaagagtacg gtttgagctg ttccgatgct ctgcataatc tttttttacat ctccaggtttc 840
atttcacaat gcacgcacatg agttggaagg agttcaacag acagacagtt tttctttatc 900
aaccggcgcc cttgtgaccc agcaaaggct tgcagactcg tgaatgaggt ctaccacatg 960
tataatcgac accagtatcc atttgttgtt cttaacattt ctggtgatcc agaatgcggt 1020
gatatcaatg ttactccaga taaaaggcaa attttgctac aagaggaaaa gcttttgttg 1080
gcagttttta agacctcttt gataggaatg tttgatagtg atgtcaacaa gctaaatgtc 1140
agtcagcagc cactgctgga tgttgaagggt aacttaataa aaatgcacgc agcggatttg 1200
gaaaagccca tggtagaaaa gcaggatcaa tccccttcac taaggactgg agaagaaaaa 1260
aaagacgtgt ccatttccag actgcgagag gccttttctc ttctgtcacac aacagagaac 1320
aagcctcaca gcccaaagac tccagaacca agaaggagcc ctctaggaca gaaaaggggt 1380
atgctgtctt ctagcacttc aggtgccatc tctgacaaag gcgtcctgag acctcagaaa 1440
gaggcagtg gttccagtca cggacccagt gaccctacgg acagagcgga ggtggagaag 1500
gactcggggc acggcagcac ttccgtggat tctgaggggt tcagcatccc agacacgggc 1560
agtcactgca gcagcgagta tgcggccagc tcccagggg acaggggctc gcagggaacat 1620
gtggactctc aggagaaagc gctgaaact gacgactctt tttcagatgt ggactgccat 1680
tcaaaccagg aagataccgg atgtaaattt cgagttttgc ctccagccaac taatctcgca 1740
accccaaaca caaagcgttt taaaaaagaa gaaattcttt ccagttctga catttgcac 1800
aagttagtaa atactcagga catgtcagcc tctcaggttg atgtagctgt gaaaattaat 1860
aagaaagttg tgcccttgga cttttctatg agttctttag ctaaacgaat aaagcagtta 1920
catcatgaag cacagcaaag tgaaggggaa cagaattaca ggaagtttag ggcaaagatt 1980
tgtcctggag aaaatcaagc agccgaagat gaactaagaa aagagataag taaaacgatg 2040
tttgagaaaa tggaaatcat tggtcagttt aacctgggat ttataataac caaactgaat 2100
gaggatatct tcatagtgga ccagcatgcc acggacgaga agtataactt cgagatgctg 2160
cagcagcaca ccgtgctcca ggggcagagg ctcatagcac ctccagactct caacttaact 2220
gctgttaatg aagctgttct gatagaaaat ctggaaatat ttagaaagaa tggctttgat 2280
tttgttatcg atgaaaatgc tccagtcact gaaagggcta aactgatttc cttgccaaact 2340
agtaaaaaact ggaccttcgg accccaggac gtogatgaac tgatcttcat gctgagcgac 2400
agccctgggg tcatgtgccg gccttcccg gtcacagcaga tgtttgctc cagagcctgc 2460
cggaagtcgg tgatgattgg gactgctctt aacacaagcg agatgaagaa actgatcacc 2520
cacatggggg agatggacca cccctggaac tgtcccatg gaaggccaac catgagacac 2580
atcgccaacc tgggtgtcat ttctcagaac tgaccgtagt cactgtatgg aataattggt 2640
tttatcgag atttttatgt tttgaaagac agagtcttca ctaacctttt ttgtttttaa 2700
atgaaacctg ctacttaaaa aaaatacaca tcacacctat ttaaaagtga tcttgagaac 2760
cttttcaaac c 2771

```

MOR0312.ST25.txt

<210> 9  
 <211> 932  
 <212> PRT  
 <213> Homo sapiens

<400> 9

Met Lys Gln Leu Pro Ala Ala Thr Val Arg Leu Leu Ser Ser Ser Gln  
 1 5 10 15

Ile Ile Thr Ser Val Val Ser Val Val Lys Glu Leu Ile Glu Asn Ser  
 20 25 30

Leu Asp Ala Gly Ala Thr Ser Val Asp Val Lys Leu Glu Asn Tyr Gly  
 35 40 45

Phe Asp Lys Ile Glu Val Arg Asp Asn Gly Glu Gly Ile Lys Ala Val  
 50 55 60

Asp Ala Pro Val Met Ala Met Lys Tyr Tyr Thr Ser Lys Ile Asn Ser  
 65 70 75 80

His Glu Asp Leu Glu Asn Leu Thr Thr Tyr Gly Phe Arg Gly Glu Ala  
 85 90 95

Leu Gly Ser Ile Cys Cys Ile Ala Glu Val Leu Ile Thr Thr Arg Thr  
 100 105 110

Ala Ala Asp Asn Phe Ser Thr Gln Tyr Val Leu Asp Gly Ser Gly His  
 115 120 125

Ile Leu Ser Gln Lys Pro Ser His Leu Gly Gln Gly Thr Thr Val Thr  
 130 135 140

Ala Leu Arg Leu Phe Lys Asn Leu Pro Val Arg Lys Gln Phe Tyr Ser  
 145 150 155 160

Thr Ala Lys Lys Cys Lys Asp Glu Ile Lys Lys Ile Gln Asp Leu Leu  
 165 170 175

Met Ser Phe Gly Ile Leu Lys Pro Asp Leu Arg Ile Val Phe Val His  
 180 185 190

Asn Lys Ala Val Ile Trp Gln Lys Ser Arg Val Ser Asp His Lys Met  
 195 200 205

Ala Leu Met Ser Val Leu Gly Thr Ala Val Met Asn Asn Met Glu Ser  
 210 215 220

Phe Gln Tyr His Ser Glu Glu Ser Gln Ile Tyr Leu Ser Gly Phe Leu  
 225 230 235 240

Pro Lys Cys Asp Ala Asp His Ser Phe Thr Ser Leu Ser Thr Pro Glu  
 245 250 255

## MOR0312.ST25.txt

Arg Ser Phe Ile Phe Ile Asn Ser Arg Pro Val His Gln Lys Asp Ile  
 260 265 270  
 Leu Lys Leu Ile Arg His His Tyr Asn Leu Lys Cys Leu Lys Glu Ser  
 275 280 285  
 Thr Arg Leu Tyr Pro Val Phe Phe Leu Lys Ile Asp Val Pro Thr Ala  
 290 295 300  
 Asp Val Asp Val Asn Leu Thr Pro Asp Lys Ser Gln Val Leu Leu Gln  
 305 310 315 320  
 Asn Lys Glu Ser Val Leu Ile Ala Leu Glu Asn Leu Met Thr Thr Cys  
 325 330 335  
 Tyr Gly Pro Leu Pro Ser Thr Asn Ser Tyr Glu Asn Asn Lys Thr Asp  
 340 345 350  
 Val Ser Ala Ala Asp Ile Val Leu Ser Lys Thr Ala Glu Thr Asp Val  
 355 360 365  
 Leu Phe Asn Lys Val Glu Ser Ser Gly Lys Asn Tyr Ser Asn Val Asp  
 370 375 380  
 Thr Ser Val Ile Pro Phe Gln Asn Asp Met His Asn Asp Glu Ser Gly  
 385 390 395 400  
 Lys Asn Thr Asp Asp Cys Leu Asn His Gln Ile Ser Ile Gly Asp Phe  
 405 410 415  
 Gly Tyr Gly His Cys Ser Ser Glu Ile Ser Asn Ile Asp Lys Asn Thr  
 420 425 430  
 Lys Asn Ala Phe Gln Asp Ile Ser Met Ser Asn Val Ser Trp Glu Asn  
 435 440 445  
 Ser Gln Thr Glu Tyr Ser Lys Thr Cys Phe Ile Ser Ser Val Lys His  
 450 455 460  
 Thr Gln Ser Glu Asn Gly Asn Lys Asp His Ile Asp Glu Ser Gly Glu  
 465 470 475 480  
 Asn Glu Glu Glu Ala Gly Leu Glu Asn Ser Ser Glu Ile Ser Ala Asp  
 485 490 495  
 Glu Trp Ser Arg Gly Asn Ile Leu Lys Asn Ser Val Gly Glu Asn Ile  
 500 505 510  
 Glu Pro Val Lys Ile Leu Val Pro Glu Lys Ser Leu Pro Cys Lys Val  
 515 520 525  
 Ser Asn Asn Asn Tyr Pro Ile Pro Glu Gln Met Asn Leu Asn Glu Asp



MOR0312.ST25.txt

530	535	540
Ser Cys Asn Lys Lys	Ser Asn Val Ile Asp Asn Lys Ser Gly Lys Val	
545	550	555 560
Thr Ala Tyr Asp Leu Leu Ser Asn Arg Val Ile Lys Lys Pro Met Ser		
	565	570 575
Ala Ser Ala Leu Phe Val Gln Asp His Arg Pro Gln Phe Leu Ile Glu		
	580	585 590
Asn Pro Lys Thr Ser Leu Glu Asp Ala Thr Leu Gln Ile Glu Glu Leu		
	595	600 605
Trp Lys Thr Leu Ser Glu Glu Glu Lys Leu Lys Tyr Glu Glu Lys Ala		
	610	615 620
Thr Lys Asp Leu Glu Arg Tyr Asn Ser Gln Met Lys Arg Ala Ile Glu		
	625	630 635 640
Gln Glu Ser Gln Met Ser Leu Lys Asp Gly Arg Lys Lys Ile Lys Pro		
	645	650 655
Thr Ser Ala Trp Asn Leu Ala Gln Lys His Lys Leu Lys Thr Ser Leu		
	660	665 670
Ser Asn Gln Pro Lys Leu Asp Glu Leu Leu Gln Ser Gln Ile Glu Lys		
	675	680 685
Arg Arg Ser Gln Asn Ile Lys Met Val Gln Ile Pro Phe Ser Met Lys		
	690	695 700
Asn Leu Lys Ile Asn Phe Lys Lys Gln Asn Lys Val Asp Leu Glu Glu		
	705	710 715 720
Lys Asp Glu Pro Cys Leu Ile His Asn Leu Arg Phe Pro Asp Ala Trp		
	725	730 735
Leu Met Thr Ser Lys Thr Glu Val Met Leu Leu Asn Pro Tyr Arg Val		
	740	745 750
Glu Glu Ala Leu Leu Phe Lys Arg Leu Leu Glu Asn His Lys Leu Pro		
	755	760 765
Ala Glu Pro Leu Glu Lys Pro Ile Met Leu Thr Glu Ser Leu Phe Asn		
	770	775 780
Gly Ser His Tyr Leu Asp Val Leu Tyr Lys Met Thr Ala Asp Asp Gln		
	785	790 795 800
Arg Tyr Ser Gly Ser Thr Tyr Leu Ser Asp Pro Arg Leu Thr Ala Asn		
	805	810 815

## MOR0312.ST25.txt

Gly Phe Lys Ile Lys Leu Ile Pro Gly Val Ser Ile Thr Glu Asn Tyr  
820 825 830

Leu Glu Ile Glu Gly Met Ala Asn Cys Leu Pro Phe Tyr Gly Val Ala  
835 840 845

Asp Leu Lys Glu Ile Leu Asn Ala Ile Leu Asn Arg Asn Ala Lys Glu  
850 855 860

Val Tyr Glu Cys Arg Pro Arg Lys Val Ile Ser Tyr Leu Glu Gly Glu  
865 870 875 880

Ala Val Arg Leu Ser Arg Gln Leu Pro Met Tyr Leu Ser Lys Glu Asp  
885 890 895

Ile Gln Asp Ile Ile Tyr Arg Met Lys His Gln Phe Gly Asn Glu Ile  
900 905 910

Lys Glu Cys Val His Gly Arg Pro Phe Phe His His Leu Thr Tyr Leu  
915 920 925

Pro Glu Thr Thr  
930

<210> 10  
<211> 3063  
<212> DNA  
<213> Homo sapiens

<400> 10  
ggcacgagtg gctgcttgcg gctagtggat ggtaattgcc tgcctcgcg tagcagcaag 60  
ctgctctgtt aaaagcgaaa atgaaacaat tgctgcggc aacagttcga ctcttttcaa 120  
gttctcagat catcacttcg gtggtcagtg ttgtaaaaga gcttattgaa aactccttgg 180  
atgctggtgc cacaagcgta gatgttaaac tggagaacta tggatttgat aaaattgagg 240  
tgcgagataa cggggagggt atcaaggctg ttgatgcacc tgtaatggca atgaagtact 300  
acacctcaaa aataaatagt catgaagatc ttgaaaattt gacaacttac ggttttcgtg 360  
gagaagcctt ggggtcaatt tgttgtatag ctgagggtttt aattacaaca agaacggctg 420  
ctgataattt tagcaccag tatgttttag atggcagtg ccacatactt tctcagaaac 480  
cttcacatct tgggtcaagg acaactgtaa ctgctttaag attatttaag aatctacctg 540  
taagaaagca gttttactca actgcaaaaa aatgtaaaga tgaaataaaa aagatccaag 600  
atctctcat gagctttggt atccttaaac ctgacttaag gattgtcttt gtacataaca 660  
aggcagttat ttggcagaaa agcagagtat cagatcaca gatggctctc atgtcagttc 720  
tggggactgc tgttatgaac aatatggaat cctttcagta ccaactctgaa gaatctcaga 780  
tttatctcag tggatttctt ccaagtggtg atgcagacca ctctttcact agtctttcaa 840  
caccagaaag aagtttcato ttcataaaca gtcgaccagt acatcaaaaa gatattctta 900  
agttaatccg acatcattac aatctgaaat gcctaaagga atctactcgt ttgtatcctg 960

## MOR0312.ST25.txt

ttttctttct	gaaaatcgat	gttcctacag	ctgatgttga	tgtaaaatta	acaccagata	1020
aaagccaagt	attattacaa	aataaggaat	ctgttttaat	tgctcttgaa	aatctgatga	1080
cgacttgta	tggaaccatta	cctagtacaa	attcttatga	aaataataaa	acagatgttt	1140
ccgcagctga	catcgttctt	agtaaaacag	cagaaacaga	tgtgcttttt	aataaagtgg	1200
aatcatctgg	aaagaattat	tcaaatgttg	atacttcagt	cattccatto	caaaatgata	1260
tgcataatga	tgaatctgga	aaaaacactg	atgattgttt	aatcaccag	ataagtattg	1320
gtgactttgg	ttatgggtcat	tgtagtagtg	aaatttctaa	cattgataaa	aacactaaga	1380
atgcatttca	ggacatttca	atgagtaatg	tatcatggga	gaactctcag	acggaatata	1440
gtaaaacttg	ttttataagt	tccgttaagc	acaccagtc	agaaaatggc	aataaagacc	1500
atatagatga	gagtggggaa	aatgaggaag	aagcaggtct	tgaaaactct	tcggaaattt	1560
ctgcagatga	gtggagcagg	ggaaatatac	ttaaaaattc	agtgggagag	aatattgaac	1620
ctgtgaaaat	tttagtgcct	gaaaaaagtt	taccatgtaa	agtaagtaat	aataattatc	1680
caatccctga	acaaatgaat	cttaatgaag	attcatgtaa	caaaaaatca	aatgtaatag	1740
ataataaatc	tggaagagtt	acagcttatg	atttacttag	caatcgagta	atcaagaaac	1800
ccatgtcagc	aagtgtctct	tttgttcaag	atcatcgtcc	tcagtttctc	atagaaaatc	1860
ctaagactag	tttagaggat	gcaacactac	aaattgaaga	actgtggaag	acattgagtg	1920
aagaggaaaa	actgaaatat	gaagagaagg	ctactaaaga	cttggaacga	tacaatagtc	1980
aatgaagag	agccattgaa	caggagtcac	aaatgtcact	aaaagatggc	agaaaaaaga	2040
taaaaccac	cagcgcatgg	aatttggtccc	agaagcacia	gttaaaaacc	tcattatcta	2100
atcaacccaa	acttgatgaa	ctccttcagt	cccaaatga	aaaaagaagg	agtcaaaata	2160
ttaaaatgg	acagatcccc	ttttctatga	aaaacttaaa	aataaatttt	aagaacaaa	2220
acaaagtga	cttagaagag	aaggatgaac	cttgcttgat	ccacaatctc	aggtttctctg	2280
atgcatggct	aatgacatcc	aaaacagagg	taatgttatt	aatccatat	agagtagaag	2340
aagccctgct	atttaaaaga	cttcttgaga	atcataaact	tctgcagag	ccactggaaa	2400
agccaattat	gttaacagag	agtcttttta	atggatctca	ttatttagac	gttttatata	2460
aatgacagc	agatgaccaa	agatacagtg	gatcaactta	cctgtctgat	cctcgtctta	2520
cagcgaatgg	tttcaagata	aaattgatac	caggagtttc	aattactgaa	aattacttgg	2580
aatagaagg	aatggcta	tgtctcccat	tctatggagt	agcagattta	aaagaaattc	2640
ttaatgctat	attaaacaga	aatgcaaagg	aagtttatga	atgtagacct	cgcaaagtga	2700
taagtatttt	agaggagaa	gcagtgcgtc	tatccagaca	attacccatg	tacttatcaa	2760
aagaggacat	ccaagacatt	atctacagaa	tgaagcacca	gtttggaaat	gaaattaaag	2820
agtgtgttca	tggtcgccca	ttttttcatc	atttaacota	tcttccagaa	actacatgat	2880
taaatatgtt	taagaagatt	agttaccatt	gaaattgggt	ctgtcataaa	acagcatgag	2940
tctggtttta	aattatcttt	gtattatgtg	tcacatgggt	attttttaaa	tgaggattca	3000
ctgacttggt	tttatattga	aaaaagttcc	acgtatttga	gaaaacgtaa	ataaactaat	3060

MOR0312.ST25.txt

aac

3063

<210> 11  
 <211> 934  
 <212> PRT  
 <213> Homo sapiens

<400> 11

Met Ala Val Gln Pro Lys Glu Thr Leu Gln Leu Glu Ser Ala Ala Glu  
 1 5 10 15

Val Gly Phe Val Arg Phe Phe Gln Gly Met Pro Glu Lys Pro Thr Thr  
 20 25 30

Thr Val Arg Leu Phe Asp Arg Gly Asp Phe Tyr Thr Ala His Gly Glu  
 35 40 45

Asp Ala Leu Leu Ala Ala Arg Glu Val Phe Lys Thr Gln Gly Val Ile  
 50 55 60

Lys Tyr Met Gly Pro Ala Gly Ala Lys Asn Leu Gln Ser Val Val Leu  
 65 70 75 80

Ser Lys Met Asn Phe Glu Ser Phe Val Lys Asp Leu Leu Leu Val Arg  
 85 90 95

Gln Tyr Arg Val Glu Val Tyr Lys Asn Arg Ala Gly Asn Lys Ala Ser  
 100 105 110

Lys Glu Asn Asp Trp Tyr Leu Ala Tyr Lys Ala Ser Pro Gly Asn Leu  
 115 120 125

Ser Gln Phe Glu Asp Ile Leu Phe Gly Asn Asn Asp Met Ser Ala Ser  
 130 135 140

Ile Gly Val Val Gly Val Lys Met Ser Ala Val Asp Gly Gln Arg Gln  
 145 150 155 160

Val Gly Val Gly Tyr Val Asp Ser Ile Gln Arg Lys Leu Gly Leu Cys  
 165 170 175

Glu Phe Pro Asp Asn Asp Gln Phe Ser Asn Leu Glu Ala Leu Leu Ile  
 180 185 190

Gln Ile Gly Pro Lys Glu Cys Val Leu Pro Gly Gly Glu Thr Ala Gly  
 195 200 205

Asp Met Gly Lys Leu Arg Gln Ile Ile Gln Arg Gly Gly Ile Leu Ile  
 210 215 220

Thr Glu Arg Lys Lys Ala Asp Phe Ser Thr Lys Asp Ile Tyr Gln Asp  
 225 230 235 240

Leu	Asn	Arg	Leu	Leu	Lys	Gly	Lys	Lys	Gly	Glu	Gln	Met	Asn	Ser	Ala	
				245						250					255	
Val	Leu	Pro	Glu	Met	Glu	Asn	Gln	Val	Ala	Val	Ser	Ser	Leu	Ser	Ala	
			260					265					270			
Val	Ile	Lys	Phe	Leu	Glu	Leu	Leu	Ser	Asp	Asp	Ser	Asn	Phe	Gly	Gln	
		275					280					285				
Phe	Glu	Leu	Thr	Thr	Phe	Asp	Phe	Ser	Gln	Tyr	Met	Lys	Leu	Asp	Ile	
	290					295					300					
Ala	Ala	Val	Arg	Ala	Leu	Asn	Leu	Phe	Gln	Gly	Ser	Val	Glu	Asp	Thr	
305					310					315					320	
Thr	Gly	Ser	Gln	Ser	Leu	Ala	Ala	Leu	Leu	Asn	Lys	Cys	Lys	Thr	Pro	
				325					330					335		
Gln	Gly	Gln	Arg	Leu	Val	Asn	Gln	Trp	Ile	Lys	Gln	Pro	Leu	Met	Asp	
			340					345					350			
Lys	Asn	Arg	Ile	Glu	Glu	Arg	Leu	Asn	Leu	Val	Glu	Ala	Phe	Val	Glu	
		355					360					365				
Asp	Ala	Glu	Leu	Arg	Gln	Thr	Leu	Gln	Glu	Asp	Leu	Leu	Arg	Arg	Phe	
	370					375					380					
Pro	Asp	Leu	Asn	Arg	Leu	Ala	Lys	Lys	Phe	Gln	Arg	Gln	Ala	Ala	Asn	
385					390					395					400	
Leu	Gln	Asp	Cys	Tyr	Arg	Leu	Tyr	Gln	Gly	Ile	Asn	Gln	Leu	Pro	Asn	
				405					410					415		
Val	Ile	Gln	Ala	Leu	Glu	Lys	His	Glu	Gly	Lys	His	Gln	Lys	Leu	Leu	
			420					425					430			
Leu	Ala	Val	Phe	Val	Thr	Pro	Leu	Thr	Asp	Leu	Arg	Ser	Asp	Phe	Ser	
		435					440					445				
Lys	Phe	Gln	Glu	Met	Ile	Glu	Thr	Thr	Leu	Asp	Met	Asp	Gln	Val	Glu	
	450					455					460					
Asn	His	Glu	Phe	Leu	Val	Lys	Pro	Ser	Phe	Asp	Pro	Asn	Leu	Ser	Glu	
465					470					475					480	
Leu	Arg	Glu	Ile	Met	Asn	Asp	Leu	Glu	Lys	Lys	Met	Gln	Ser	Thr	Leu	
				485					490					495		
Ile	Ser	Ala	Ala	Arg	Asp	Leu	Gly	Leu	Asp	Pro	Gly	Lys	Gln	Ile	Lys	
		500						505					510			
Leu	Asp	Ser	Ser	Ala	Gln	Phe	Gly	Tyr	Tyr	Phe	Arg	Val	Thr	Cys	Lys	

MOR0312.ST25.txt

515	520	525
Glu Glu Lys Val Leu Arg Asn Asn Lys Asn Phe Ser Thr Val Asp Ile 530 535 540		
Gln Lys Asn Gly Val Lys Phe Thr Asn Ser Lys Leu Thr Ser Leu Asn 545 550 555 560		
Glu Glu Tyr Thr Lys Asn Lys Thr Glu Tyr Glu Glu Ala Gln Asp Ala 565 570 575		
Ile Val Lys Glu Ile Val Asn Ile Ser Ser Gly Tyr Val Glu Pro Met 580 585 590		
Gln Thr Leu Asn Asp Val Leu Ala Gln Leu Asp Ala Val Val Ser Phe 595 600 605		
Ala His Val Ser Asn Gly Ala Pro Val Pro Tyr Val Arg Pro Ala Ile 610 615 620		
Leu Glu Lys Gly Gln Gly Arg Ile Ile Leu Lys Ala Ser Arg His Ala 625 630 635 640		
Cys Val Glu Val Gln Asp Glu Ile Ala Phe Ile Pro Asn Asp Val Tyr 645 650 655		
Phe Glu Lys Asp Lys Gln Met Phe His Ile Ile Thr Gly Pro Asn Met 660 665 670		
Gly Gly Lys Ser Thr Tyr Ile Arg Gln Thr Gly Val Ile Val Leu Met 675 680 685		
Ala Gln Ile Gly Cys Phe Val Pro Cys Glu Ser Ala Glu Val Ser Ile 690 695 700		
Val Asp Cys Ile Leu Ala Arg Val Gly Ala Gly Asp Ser Gln Leu Lys 705 710 715 720		
Gly Val Ser Thr Phe Met Ala Glu Met Leu Glu Thr Ala Ser Ile Leu 725 730 735		
Arg Ser Ala Thr Lys Asp Ser Leu Ile Ile Ile Asp Glu Leu Gly Arg 740 745 750		
Gly Thr Ser Thr Tyr Asp Gly Phe Gly Leu Ala Trp Ala Ile Ser Glu 755 760 765		
Tyr Ile Ala Thr Lys Ile Gly Ala Phe Cys Met Phe Ala Thr His Phe 770 775 780		
His Glu Leu Thr Ala Leu Ala Asn Gln Ile Pro Thr Val Asn Asn Leu 785 790 795 800		

## MOR0312.ST25.txt

His Val Thr Ala Leu Thr Thr Glu Glu Thr Leu Thr Met Leu Tyr Gln  
805 810 815

Val Lys Lys Gly Val Cys Asp Gln Ser Phe Gly Ile His Val Ala Glu  
820 825 830

Leu Ala Asn Phe Pro Lys His Val Ile Glu Cys Ala Lys Gln Lys Ala  
835 840 845

Leu Glu Leu Glu Glu Phe Gln Tyr Ile Gly Glu Ser Gln Gly Tyr Asp  
850 855 860

Ile Met Glu Pro Ala Ala Lys Lys Cys Tyr Leu Glu Arg Glu Gln Gly  
865 870 875 880

Glu Lys Ile Ile Gln Glu Phe Leu Ser Lys Val Lys Gln Met Pro Phe  
885 890 895

Thr Glu Met Ser Glu Glu Asn Ile Thr Ile Lys Leu Lys Gln Leu Lys  
900 905 910

Ala Glu Val Ile Ala Lys Asn Asn Ser Phe Val Asn Glu Ile Ile Ser  
915 920 925

Arg Ile Lys Val Thr Thr  
930

<210> 12  
<211> 3145  
<212> DNA  
<213> Homo sapiens

<400> 12  
ggcgggaaac agcttagtgg gtgtggggtc gcgcattttc ttcaaccagg aggtgaggag 60  
gtttcgacat ggcggtgcag ccgaaggaga cgctgcagtt ggagagcgcg gccgaggtcg 120  
gcttcgtgcg cttctttcag ggcacgccgg agaagccgac caccacagtg cgctttttcg 180  
accggggcga cttctatacg gcgcacggcg aggacgcgct gctggccgcc cgggaggtgt 240  
tcaagacca gggggtgata aagtacatgg ggccggcagg agcaaagaat ctgcagagtg 300  
ttgtgcttag taaaatgaat tttgaatctt ttgtaaaaga tcttcttctg gttcgtcagt 360  
atagagttga agtttataag aatagagctg gaaataaggc atccaaggag aatgattggt 420  
at ttggcata taaggcttct cctggcaatc tctctcagtt tgaagacatt ctctttggta 480  
acaatgatat gtcagcttcc attggtgttg tgggtgttaa aatgtccgca gttgatggcc 540  
agagacaggt tggagttggg tatgtggatt ccatacagag gaaactagga ctgtgtgaat 600  
tccctgataa tgatcagttc tccaatcttg aggcctctct catccagatt ggaccaaagg 660  
aatgtgtttt acccggagga gagactgctg gagacatggg gaaactgaga cagataattc 720  
aaagaggagg aattctgata acagaaagaa aaaaagctga cttttccaca aaagacattt 780  
atcaggacct caaccggttg ttgaaaggca aaaagggaga gcagatgaat agtgctgtat 840

## MOR0312.ST25.txt

tgccagaaat ggagaatcag gttgcagttt catcactgtc tgcggtaatc aagtttttag	900
aactottatc agatgattcc aactttggac agtttgaact gactactttt gacttcagcc	960
agtatatgaa attggatatt gcagcagtc gagcccttaa cctttttcag ggttctgttg	1020
aagataccac tggctctcag tctctggctg ccttgtgaa taagtgtaaa acccctcaag	1080
gacaaagact tgtaaccag tggattaagc agcctctcat ggataagaac agaatagagg	1140
agagattgaa tttagtggaa gctttttag aagatgcaga attgaggcag actttacaag	1200
aagatttact tcgtcgattc ccagatctta accgacttgc caagaagttt caaagacaag	1260
cagcaactt acaagattgt taccgactct atcagggat aaatcaacta cctaattgta	1320
tacaggctct ggaaaaacat gaaggaaaac accagaaatt attgttgga gtttttgtga	1380
ctcctcttac tgatcttcgt tctgacttct ccaagtttca ggaaatgata gaaacaactt	1440
tagatatgga tcagggtgaa aaccatgaat tccttgtaaa accttcattt gatcctaata	1500
tcagtgaatt aagagaaata atgaatgact tggaaaagaa gatgcagtc acattaataa	1560
gtgcagccag agatcttggc ttggaccctg gcaaacagat taaactggat tccagtgcac	1620
agtttgata ttactttcgt gtaacctgta aggaagaaaa agtccttcgt aacaataaaa	1680
acttttagtac tgtagatata cagaagaatg gtgttaaatt taccaacagc aaattgactt	1740
ctttaaatga agagtatacc aaaaaataaa cagaatatga agaagcccag gatgccattg	1800
ttaaagaaat tgtcaatatt tcttcaggct atgtagaacc aatgcagaca ctcaatgatg	1860
tgttagctca gctagatgct gttgtcagct ttgctcacgt gtcaaagga gcacctgttc	1920
catatgtacg accagccatt ttggagaaag gacaaggaag aattatatta aaagcatcca	1980
ggcatgcttg tgttgaagtt caagatgaaa ttgcatttat tctaatagac gtatactttg	2040
aaaaagataa acagatgttc cacatcatta ctggcccca tatgggaggt aaatcaacat	2100
atattcgaca aactggggtg atagtactca tggcccaaat tgggtgtttt gtgccatgtg	2160
agtcagcaga agtgtccatt gtggactgca tcttagccc agtaggggct ggtgacagtc	2220
aattgaaagg agtctccacg ttcattggctg aaatgttgga aactgcttct atcctcaggt	2280
ctgcaaccaa agattcatta ataatcatag atgaattggg aagaggaact tctacctacg	2340
atggatttgg gttagcatgg gctatatcag aatacattgc aacaaagatt ggtgcttttt	2400
gcatgtttgc aaccttttt catgaactta ctgccttggc caatcagata ccaactgtta	2460
ataatctaca tgtcacagca ctccacctg aagagacott aactatgctt tatcagggtga	2520
agaaagggtg ctgtgatcaa agttttggga ttcattgtgc agagcttgct aatttcctta	2580
agcatgtaat agagtgtgct aaacagaaag ccctggaact tgaggagttt cagtatattg	2640
gagaatcgca aggatatgat atcatggaac cagcagcaaa gaagtgtat ctggaaagag	2700
agcaagggtga aaaaattatt caggagttcc tgtccaagg gaaacaaatg ccctttactg	2760
aaatgtcaga agaaaacatc acaataaagt taaaacagct aaaagctgaa gtaatagcaa	2820
agaataatag ctttgtaaat gaaatcattt caccgataaa agttactacg tgaaaaatcc	2880
cagtaatgga atgaaggtaa tattgataag ctattgtctg taatagtttt atattgtttt	2940



MOR0312.ST25.txt

atattaaccc tttttccata gtgttaactg tcagtgccca tgggctatca acttaataag 3000  
 atatttagta atattttact ttgaggacat tttcaaagat ttttattttg aaaaatgaga 3060  
 gctgtaactg aggactgttt gcaattgaca taggcaataa taagtgatgt gctgaatttt 3120  
 ataaataaaa tcatgtagtt tgtgg 3145

<210> 13  
 <211> 756  
 <212> PRT  
 <213> Homo sapiens

<400> 13

Met Ser Phe Val Ala Gly Val Ile Arg Arg Leu Asp Glu Thr Val Val  
 1 5 10 15

Asn Arg Ile Ala Ala Gly Glu Val Ile Gln Arg Pro Ala Asn Ala Ile  
 20 25 30

Lys Glu Met Ile Glu Asn Cys Leu Asp Ala Lys Ser Thr Ser Ile Gln  
 35 40 45

Val Ile Val Lys Glu Gly Gly Leu Lys Leu Ile Gln Ile Gln Asp Asn  
 50 55 60

Gly Thr Gly Ile Arg Lys Glu Asp Leu Asp Ile Val Cys Glu Arg Phe  
 65 70 75 80

Thr Thr Ser Lys Leu Gln Ser Phe Glu Asp Leu Ala Ser Ile Ser Thr  
 85 90 95

Tyr Gly Phe Arg Gly Glu Ala Leu Ala Ser Ile Ser His Val Ala His  
 100 105 110

Val Thr Ile Thr Thr Lys Thr Ala Asp Gly Lys Cys Ala Tyr Arg Ala  
 115 120 125

Ser Tyr Ser Asp Gly Lys Leu Lys Ala Pro Pro Lys Pro Cys Ala Gly  
 130 135 140

Asn Gln Gly Thr Gln Ile Thr Val Glu Asp Leu Phe Tyr Asn Ile Ala  
 145 150 155 160

Thr Arg Arg Lys Ala Leu Lys Asn Pro Ser Glu Glu Tyr Gly Lys Ile  
 165 170 175

Leu Glu Val Val Gly Arg Tyr Ser Val His Asn Ala Gly Ile Ser Phe  
 180 185 190

Ser Val Lys Lys Gln Gly Glu Thr Val Ala Asp Val Arg Thr Leu Pro  
 195 200 205

Asn Ala Ser Thr Val Asp Asn Ile Arg Ser Ile Phe Gly Asn Ala Val

MOR0312.ST25.txt

210	215	220
Ser Arg Glu Leu Ile Glu Ile Gly Cys Glu Asp Lys Thr Leu Ala Phe		
225	230	235 240
Lys Met Asn Gly Tyr Ile Ser Asn Ala Asn Tyr Ser Val Lys Lys Cys		
	245	250 255
Ile Phe Leu Leu Phe Ile Asn His Arg Leu Val Glu Ser Thr Ser Leu		
	260	265 270
Arg Lys Ala Ile Glu Thr Val Tyr Ala Ala Tyr Leu Pro Lys Asn Thr		
	275	280 285
His Pro Phe Leu Tyr Leu Ser Leu Glu Ile Ser Pro Gln Asn Val Asp		
	290	295 300
Val Asn Val His Pro Thr Lys His Glu Val His Phe Leu His Glu Glu		
305	310	315 320
Ser Ile Leu Glu Arg Val Gln Gln His Ile Glu Ser Lys Leu Leu Gly		
	325	330 335
Ser Asn Ser Ser Arg Met Tyr Phe Thr Gln Thr Leu Leu Pro Gly Leu		
	340	345 350
Ala Gly Pro Ser Gly Glu Met Val Lys Ser Thr Thr Ser Leu Thr Ser		
	355	360 365
Ser Ser Thr Ser Gly Ser Ser Asp Lys Val Tyr Ala His Gln Met Val		
	370	375 380
Arg Thr Asp Ser Arg Glu Gln Lys Leu Asp Ala Phe Leu Gln Pro Leu		
385	390	395 400
Ser Lys Pro Leu Ser Ser Gln Pro Gln Ala Ile Val Thr Glu Asp Lys		
	405	410 415
Thr Asp Ile Ser Ser Gly Arg Ala Arg Gln Gln Asp Glu Glu Met Leu		
	420	425 430
Glu Leu Pro Ala Pro Ala Glu Val Ala Ala Lys Asn Gln Ser Leu Glu		
	435	440 445
Gly Asp Thr Thr Lys Gly Thr Ser Glu Met Ser Glu Lys Arg Gly Pro		
	450	455 460
Thr Ser Ser Asn Pro Arg Lys Arg His Arg Glu Asp Ser Asp Val Glu		
465	470	475 480
Met Val Glu Asp Asp Ser Arg Lys Glu Met Thr Ala Ala Cys Thr Pro		
	485	490 495

## MOR0312.ST25.txt

Arg Arg Arg Ile Ile Asn Leu Thr Ser Val Leu Ser Leu Gln Glu Glu  
 500 505 510  
 Ile Asn Glu Gln Gly His Glu Val Leu Arg Glu Met Leu His Asn His  
 515 520 525  
 Ser Phe Val Gly Cys Val Asn Pro Gln Trp Ala Leu Ala Gln His Gln  
 530 535 540  
 Thr Lys Leu Tyr Leu Leu Asn Thr Thr Lys Leu Ser Glu Glu Leu Phe  
 545 550 555 560  
 Tyr Gln Ile Leu Ile Tyr Asp Phe Ala Asn Phe Gly Val Leu Arg Leu  
 565 570 575  
 Ser Glu Pro Ala Pro Leu Phe Asp Leu Ala Met Leu Ala Leu Asp Ser  
 580 585 590  
 Pro Glu Ser Gly Trp Thr Glu Glu Asp Gly Pro Lys Glu Gly Leu Ala  
 595 600 605  
 Glu Tyr Ile Val Glu Phe Leu Lys Lys Lys Ala Glu Met Leu Ala Asp  
 610 615 620  
 Tyr Phe Ser Leu Glu Ile Asp Glu Glu Gly Asn Leu Ile Gly Leu Pro  
 625 630 635 640  
 Leu Leu Ile Asp Asn Tyr Val Pro Pro Leu Glu Gly Leu Pro Ile Phe  
 645 650 655  
 Ile Leu Arg Leu Ala Thr Glu Val Asn Trp Asp Glu Glu Lys Glu Cys  
 660 665 670  
 Phe Glu Ser Leu Ser Lys Glu Cys Ala Met Phe Tyr Ser Ile Arg Lys  
 675 680 685  
 Gln Tyr Ile Ser Glu Glu Ser Thr Leu Ser Gly Gln Gln Ser Glu Val  
 690 695 700  
 Pro Gly Ser Ile Pro Asn Ser Trp Lys Trp Thr Val Glu His Ile Val  
 705 710 715 720  
 Tyr Lys Ala Leu Arg Ser His Ile Leu Pro Pro Lys His Phe Thr Glu  
 725 730 735  
 Asp Gly Asn Ile Leu Gln Leu Ala Asn Leu Pro Asp Leu Tyr Lys Val  
 740 745 750  
 Phe Glu Arg Cys  
 755

&lt;210&gt; 14

MOR0312.ST25.txt

&lt;211&gt; 2484

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

```

cttggctctt ctggcgccaa aatgtcgttc gtggcagggg ttattcggcg gctggacgag      60
acagtgggtga accgcacgcg gccgggggaa gttatccagc ggccagctaa tgctatcaaa      120
gagatgattg agaactgttt agatgcaaaa tccacaagta ttcaagtgat tgttaaagag      180
ggaggcctga agttgattca gatccaagac aatggcaccg ggatcaggaa agaagatctg      240
gatattgtat gtgaaagggt cactactagt aaactgcagt cctttgagga tttagccagt      300
atttctacct atggctttcg aggtgaggct ttggccagca taagccatgt ggctcatgtt      360
actattacaa cgaaaacagc tgatggaaag tgtgcataca gagcaagtta ctcatatgga      420
aaactgaaag cccctcctaa accatgtgct ggcaatcaag ggaccagat cacggtggag      480
gacctttttt acaacatagc cagcaggaga aaagctttta aaaatccaag tgaagaatat      540
gggaaaattt tggaagttgt tggcagggtat tcagtacaca atgcaggcat tagtttctca      600
gttaaaaaac aaggagagac agtagctgat gttaggacac taccatgc ctcaaccgtg      660
gacaatatct gctccatctt tggaaatgct gttagttag aactgataga aattggatgt      720
gaggataaaa ccctagcctt caaaatgaat ggttacatat ccaatgcaa ctactcagt      780
aagaagtgc tcttcttact ctctcatcaac catcgtctgg tagaatcaac ttcttgaga      840
aaagccatag aaacagtgtg tgcagcctat ttgccccaaa acacacaccc attcctgtac      900
ctcagtttag aaatcagtc ccagaatgtg gatgttaatg tgcacccac aaagcatgaa      960
gttcacttcc tgcacgagga gagcatctg gagcgggtgc agcagcacat cgagagcaag     1020
ctcctgggct ccaattctc caggatgtac ttcaaccaga ctttgctacc aggacttgct     1080
ggcccctctg gggagatggt taaatccaca acaagtctga cctcgtcttc tacttctgga     1140
agtagtgata aggtctatgc ccaccagatg gttcgtacag attcccgga acagaagctt     1200
gatgcatttc tgcagcctct gagcaaacc ctgtccagtc agccccaggc cattgtcaca     1260
gaggataaga cagatatctt tagtggcagg gctaggcagc aagatgagga gatgcttgaa     1320
ctcccagccc ctgctgaagt ggctgccaaa aatcagagct tggaggggga tacaacaaag     1380
gggacttcag aaatgtcaga gaagagagga cctacttcca gcaacccag aaagagacat     1440
cggaagatt ctgatgtgga aatggtggaa gatgattccc gaaaggaaat gactgcagct     1500
tgtaccccc ggagaaggat cattaacctc actagtgtt tgagtctcca ggaagaaatt     1560
aatgagcagg gacatgagg tctccgggag atgttgata accactcctt cgtgggctgt     1620
gtgaatctc agtgggcctt ggcacagcat caaaccaagt tataccttct caacaccacc     1680
aagcttagtg aagaactgtt ctaccagata ctcatatatg attttgcaa ttttgggtgt     1740
ctcaggttat cggagccagc accgctctt gaccttgcca tgcttgctt agatagtcca     1800
gagagtggct ggacagagga agatggctcc aaagaaggac ttgctgaata cattgttgag     1860
tttctgaaga agaaggtga gatgcttgca gactatttct ctttggaat tgatgaggaa     1920
gggaacctga ttggattacc ccttctgatt gacaactatg tgccccctt ggagggactg     1980

```

## MOR0312.ST25.txt

cctatcttca ttcttcgact agccactgag gtgaattggg acgaagaaaa ggaatgtttt 2040  
 gaaagcctca gtaaagaatg cgctatgttc tattccatcc ggaagcagta catatctgag 2100  
 gagtcgaccc tctcaggcca gcagagtga gtcgctggct ccattccaaa ctcttggag 2160  
 tggactgtgg aacacattgt ctataaagcc ttgcgctcac acattctgcc tcttaaacat 2220  
 ttcacagaag atggaaatat cctgcagctt gctaacctgc ctgatctata caaagtcttt 2280  
 gagaggtgtt aaatatggtt atttatgcac tgtgggatgt gttcttcttt ctctgtattc 2340  
 cgatacaaag tgttgtatca aagtgtgata tacaagtgt accaacataa gtgttggtag 2400  
 cacttaagac ttatacttgc cttctgatag tattccttta tacacagtgg attgattata 2460  
 aataaataga tgtgtcttaa cata 2484

<210> 15  
 <211> 133  
 <212> PRT  
 <213> Homo sapiens

<400> 15

Met Glu Arg Ala Glu Ser Ser Ser Thr Glu Pro Ala Lys Ala Ile Lys  
1 5 10 15

Pro Ile Asp Arg Lys Ser Val His Gln Ile Cys Ser Gly Gln Val Val  
20 25 30

Leu Ser Leu Ser Thr Ala Val Lys Glu Leu Val Glu Asn Ser Leu Asp  
35 40 45

Ala Gly Ala Thr Asn Ile Asp Leu Lys Leu Lys Asp Tyr Gly Val Asp  
50 55 60

Leu Ile Glu Val Ser Asp Asn Gly Cys Gly Val Glu Glu Glu Asn Phe  
65 70 75 80

Glu Gly Leu Thr Leu Lys His His Thr Ser Lys Ile Gln Glu Phe Ala  
85 90 95

Asp Leu Thr Gln Val Glu Thr Phe Gly Phe Arg Gly Glu Ala Leu Ser  
100 105 110

Ser Leu Cys Ala Leu Ser Asp Val Thr Ile Ser Thr Cys His Ala Ser  
115 120 125

Ala Lys Val Gly Thr  
130

<210> 16  
 <211> 426  
 <212> DNA  
 <213> Homo sapiens

<400> 16  
 cgaggcggat cgggtgttgc atccatggag cgagctgaga gctcgagtac agaacctgct 60

## MOR0312.ST25.txt

```

aaggccatca aacctattga tcggaagtca gtccatcaga tttgctctgg gcaggtggta 120
ctgagtctaa gcactgcggt aaaggagtta gtagaaaaca gtctggatgc tggtgccact 180
aatattgatc taaagcttaa ggactatgga gtggatctta ttgaagtttc agacaatgga 240
tgtggggtag aagaagaaaa cttcgaaggc ttaactctga aacatcacac atctaagatt 300
caagagtttg ccgacctaac tcaggttgaa acttttggct ttcgggggga agctctgagc 360
tcactttgtg cactgagcga tgtcaccatt tctacctgcc acgcatcggc gaaggttgga 420
acttga 426

```

<210> 17  
 <211> 70  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Clone HB 91-47 immunoglobulin heavy chain

<400> 17

```

Leu Gln Gln Ser Gly Pro Glu Leu Gly Lys Pro Gly Thr Ser Val Lys
1           5           10           15

```

```

Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn
          20           25           30

```

```

Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile
          35           40           45

```

```

Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg
50           55           60

```

```

Phe Ala Phe Ser Leu Glu
65           70

```

<210> 18  
 <211> 70  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Parental H36 immunoglobulin heavy chain

<400> 18

```

Leu Gln Gln Ser Gly Ala Glu Leu Val Arg Pro Gly Thr Ser Val Lys
1           5           10           15

```

```

Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn
          20           25           30

```

```

Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile
          35           40           45

```

```

Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg
50           55           60

```

MOR0312.ST25.txt

Phe Ala Phe Ser Leu Glu  
65 70

<210> 19  
<211> 70  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Consensus immunoglobulin heavy chain sequence

<220>  
<221> misc\_feature  
<222> (6)..(6)  
<223> Xaa can be any naturally occurring amino acid

<220>  
<221> misc\_feature  
<222> (9)..(10)  
<223> Xaa can be any naturally occurring amino acid

<400> 19

Leu Gln Gln Ser Gly Xaa Glu Leu Xaa Xaa Pro Gly Thr Ser Val Lys  
1 5 10 15

Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr Gly Met Asn  
20 25 30

Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Lys Trp Met Gly Trp Ile  
35 40 45

Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Asp Asp Phe Lys Gly Arg  
50 55 60

Phe Ala Phe Ser Leu Glu  
65 70

<210> 20  
<211> 45  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Clone HB 91-37 immunoglobulin light chain

<400> 20

Ser Ala Ser Ser Ser Val Ser Ser Ser Tyr Phe His Trp Tyr Gln Gln  
1 5 10 15

Lys Ser Gly Ala Ser Pro Lys Pro Leu Ile His Arg Thr Ser Asn Leu  
20 25 30

Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser  
35 40 45

<210> 21

MOR0312.ST25.txt

<211> 45  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Parental immunoglobulin light chain

<400> 21

Ser Ala Ser Ser Ser Val Ser Ser Ser Tyr Phe His Trp Tyr Gln Gln  
 1 5 10 15

Lys Ser Gly Ala Ser Leu Lys Pro Leu Ile His Arg Thr Ser Asn Leu  
 20 25 30

Ala Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser  
 35 40 45

<210> 22  
 <211> 44  
 <212> PRT  
 <213> Artificial Sequence

<220>  
 <223> Consensus immunoglobulin light chain sequence

<220>  
 <221> misc\_feature  
 <222> (21)..(21)  
 <223> Xaa can be any naturally occurring amino acid

<400> 22

Ser Ala Ser Ser Ser Val Ser Ser Ser Tyr Phe Trp Tyr Gln Gln Lys  
 1 5 10 15

Ser Gly Ala Ser Xaa Lys Pro Leu Ile His Arg Thr Ser Asn Leu Ala  
 20 25 30

Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser  
 35 40

<210> 23  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Sense primer

<400> 23  
 tttcgcaacg ggtttgccg

19

<210> 24  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Antisense primer



MOR0312.ST25.txt

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (5)..(5)

&lt;223&gt; n = e

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (15)..(15)

&lt;223&gt; n = e

&lt;400&gt; 24

gtttcagagt taagccttcg

20

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 7 A61K39/395 A61K48/00 C12N5/00 C12N5/06 C12N5/16 C12N15/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K A61K C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, MEDLINE, Sequence Search		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 02/37967 A (NICOLAIDES NICHOLAS C ; MORPHOTEK INC (US); SASS PHILIP M (US); GRASSO) 16 May 2002 (2002-05-16) the whole document	1-20
P, X	WO 2004/024871 A (NICOLAIDES NICHOLAS E ; MORPHOTEK INC (US); SASS PHILIP M (US); GRASSO) 25 March 2004 (2004-03-25) the whole document	1-20
A	WO 01/32712 A (BASS STEVEN H ; KARRER ERIK (US); MAXYGEN INC (US); WHALEN ROBERT (US)) 10 May 2001 (2001-05-10) the whole document	1-20
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
16 November 2004		30/11/2004
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  Irion, A

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US2004/024436

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-19  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 1-19 are directed (at least partially) to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Int. Patent Application No  
PCT/US2004/024436

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0237967	A	16-05-2002	WO 0237967 A1	16-05-2002
			AU 1470801 A	21-05-2002
			CA 2428214 A1	16-05-2002
			EP 1345495 A1	24-09-2003
			JP 2004529613 T	30-09-2004
WO 2004024871	A	25-03-2004	US 2003143682 A1	31-07-2003
			WO 2004024871 A2	25-03-2004
WO 0132712	A	10-05-2001	AU 1456101 A	14-05-2001
			EP 1230269 A2	14-08-2002
			WO 0132712 A2	10-05-2001